

Ways to improve breast cancer patients' management and clinical outcome

Citation for published version (APA):

Aristei, C., Bölükbaşı, Y., Kaidar-Person, O., Pfeffer, R., Arenas, M., Boersma, L. J., Ciabattini, A., Coles, C. E., Franco, P., Krengli, M., Leonardi, M. C., Marazzi, F., Masiello, V., Meattini, I., Montero, A., Offersen, B., Trigo, M. L., Bourgier, C., Genovesi, D., ... Poortmans, P. (2022). Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. *Critical Reviews in Oncology/Hematology*, 177, Article 103774. <https://doi.org/10.1016/j.critrevonc.2022.103774>

Document status and date:

Published: 01/09/2022

DOI:

[10.1016/j.critrevonc.2022.103774](https://doi.org/10.1016/j.critrevonc.2022.103774)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:


repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



Contents lists available at ScienceDirect

Critical Reviews in Oncology / Hematology

journal homepage: www.elsevier.com/locate/critrevonc

Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting

Cynthia Aristei^{a,*}, Yasemin Bölükbaşı^{b,1}, Orit Kaidar-Person^{c,1}, Raphael Pfeffer^{d,1}, Meritxell Arenas^e, Liesbeth J. Boersma^f, Antonella Ciabattoni^g, Charlotte E. Coles^h, Pierfrancesco Francoⁱ, Marco Krengliⁱ, Maria Cristina Leonardi^j, Fabio Marazzi^k, Valeria Masiello^k, Icro Meattini^l, Angel Montero^m, Birgitte Offerstenⁿ, Maria Lurdes Trigo^o, Céline Bourcier^p, Domenico Genovesi^q, Vassilis Kouloulis^r, Alessio G. Morganti^{s,t}, Bruno Meduri^u, Nadia Pasinetti^v, Sara Pedretti^w, Elisabetta Perrucci^x, Sofia Rivera^y, Vincenzo Tombolini^z, Cristiana Vidali^{aa}, Vincenzo Valentini^j, Philip Poortmans^{ab}

^a Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy

^b Koc University, Faculty of Medicine, Department of Radiation Oncology, Istanbul, Turkey

^c Breast Radiation Unit, Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel

^d Oncology Institute, Assuta Medical Center, Tel Aviv and Ben Gurion University Medical School, Israel

^e Universitat Rovira I Virgili, Radiation Oncology Department, Hospital Universitari Sant Joan de Reus, IISPV, Spain

^f Radiation Oncology (Maastricht), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands

^g Department of Radiation Oncology, San Filippo Neri Hospital, ASL Rome 1, Rome, Italy

^h Department of Oncology, University of Cambridge, UK

ⁱ Department of Translational Medicine, University of Eastern Piedmont and Department of Radiation Oncology, 'Maggiore della Carità' University Hospital, Novara, Italy

^j Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy

^k Unità Operativa di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagine, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Gemelli IRCCS Roma, Italy

^l Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence & Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

^m Department of Radiation Oncology, University Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain

ⁿ Department of Experimental Clinical Oncology, Department of Oncology, Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

^o Service of Brachytherapy, Department of Image and Radioncology, Instituto Português Oncologia Porto Francisco Gentil E.P.E., Portugal

^p Radiation Oncology, ICM-Val d'Aurelle, Univ Montpellier, Montpellier, France

^q Radiation Oncology, Ospedale Clinicizzato Chieti and University "G. d'Annunzio", Chieti, Italy

^r 2nd Department of Radiology, Radiotherapy Unit, Medical School, National and Kapodistrian University of Athens, Greece

^s DIMES, Alma Mater Studiorum Bologna University, Bologna, Italy

^t Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum Bologna University; Bologna, Italy

^u Radiation Oncology Unit, University Hospital of Modena, Modena, Italy

^v Radiation Oncology Service, ASST Valcamonica Esine and Brescia University, Brescia, Italy

^w Istituto del Radio "O.Alberti" - Spedali Civili Hospital and Brescia University, Brescia

^x Radiation Oncology Section, Perugia General Hospital, Perugia, Italy

^y Radiation Oncology, Institut Gustave Roussy, Villejuif, France

^z Radiation Oncology, Department of Radiological, Oncological and Pathological Science, University "La Sapienza", Roma, Italy

^{aa} Former Senior Assistant Department of Radiation Oncology, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy

^{ab} Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium

ARTICLE INFO

Keywords:

Breast cancer
Radiation therapy
De-escalating therapy

ABSTRACT

We report on the third Assisi Think Tank Meeting (ATTM) on breast cancer, a brainstorming project which involved European radiation and clinical oncologists who were dedicated to breast cancer research and treatment. Held on February 2020, the ATTM aimed at identifying key clinical questions in current clinical practice

* Correspondence to: Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, 06156 Perugia, Italy.
E-mail address: cynthia.aristei@unipg.it (C. Aristei).

¹ the authors contributed to the same extent

<https://doi.org/10.1016/j.critrevonc.2022.103774>

Received 8 June 2021; Received in revised form 19 July 2022; Accepted 29 July 2022

Available online 30 July 2022

1040-8428/© 2022 Elsevier B.V. All rights reserved.

Stereotactic radiation therapy
 Oligometastatic disease
 BCRA-mutated patients
 Contralateral breast cancer prevention

and “grey” areas requiring research to improve management and outcomes. Before the meeting, three key topics were selected: 1) managing patients with frailty due to either age and/or multi-morbidity; 2) stereotactic radiation therapy and systemic therapy in the management of oligometastatic disease; 3) contralateral breast tumour prevention in BCRA-mutated patients. Clinical practice in these areas was investigated by means of an online questionnaire. In the lapse period between the survey and the meeting, the working groups reviewed data, on-going studies and the clinical challenges which were then discussed in-depth and subjected to intense brainstorming during the meeting; research protocols were also proposed. Methodology, outcome of discussions, conclusions and study proposals are summarized in the present paper. In conclusion, this report presents an in-depth analysis of the state of the art, grey areas and controversies in breast cancer radiation therapy and discusses how to confront them in the absence of evidence-based data to guide clinical decision-making.

1. Introduction

The “Assisi Think Tank Meeting” (ATTM), a brainstorming project on breast cancer, was first launched in 2016 (Aristei et al., 2016); it involves European radiation and clinical oncologists who are dedicated to breast cancer research and treatment and is endorsed by the European Society for RadioTherapy & Oncology (ESTRO) and by the Italian Association of Radiotherapy and Clinical Oncology (Associazione Italiana di Radioterapia e Oncologia clinica - AIRO).

The ATTM aims at identifying key clinical questions in current clinical practice and “grey” areas requiring research to improve management and outcomes, mainly related to radiation therapy (RT), including health-related quality of life (HRQoL). It expects to encourage research in the field and international collaboration. The ATTM working groups adopt systematic methods for their pre-ATTM work, surveys and presentations, with all content being evidence-based.

This white paper summarises the methodology, outcome of discussions, conclusions and study proposals of the 3rd ATTM which was held on 14th - 16th February 2020.

2. Methods

The ATTM design was described in previous white papers (Aristei et al., 2016; Arenas et al., 2020; Valentini et al., 2020). Briefly, in the months before the ATTM, controversial issues were identified through a review of the literature and clinical practice was investigated by means of an online questionnaire. Under 70% agreement on a treatment option indicated uncertainty i.e. an area of contention. Working groups reviewed data, on-going studies and the clinical challenges which were then discussed in-depth and subjected to intense brainstorming during the 3-day meeting.

For the 2020 ATTM there was consensus that the role of RT needed to be optimized and that clinical research should be conducted in each of the following topics:

- 1) Managing patients with frailty due to either age and/or multi-morbidity;
- 2) Stereotactic radiation therapy and systemic therapy in the management of oligometastatic disease;
- 3) Contralateral breast tumour prevention in BCRA-mutated patients.

3. Results

3.1. Topic 1. Managing patients with frailty due to either age and/or multi-morbidity

3.1.1. Current evidence and areas of contention

Today at diagnosis of breast cancer the approximate mean age is 60 years as it has been rising as populations have aged (Johnson et al., 2019). Rates of incidence vary with breast cancer subtypes: luminal A tumours account for 60%-70%, luminal B HER2-negative for 10%-20%, luminal B HER2-positive together with HER2-enriched non luminal for 13%-15%, and triple-negative for 10%-15% (Harbeck et al., 2019).

Current practice derives from guidelines and well-structured

randomized trials. Since many trials excluded frail and older adult patients with or without comorbidities, it is unclear how results can be applied to them (Telli et al., 2019; Biganzoli et al., 2012; Martin et al., 2011), especially as “frail” and “older adult” are not clearly defined terms. Furthermore, the definition of “older adult” has shifted over the years and now many authors would consider it as referring to people aged 70 years or more (Wildiers et al., 2007).

Oncological management should not be determined by age alone but rather by a holistic assessment of frailty and multi-morbidity, both of which tend to be more frequent in the older age-groups (Biganzoli et al., 2012). At present, “frailty” is defined by the “phenotype” and “cumulative deficit” conceptual models. The former views “frailty” as a biological syndrome and a “cycle associated with declining energetics and reserves” (Fried et al., 2001) while the latter considers it as an accumulation of deficits across a number of domains (Mitnitski et al., 2001).

Despite these uncertainties, decision-making in breast cancer needs to take into account life expectancy, patient’s health, autonomy and functional status, comorbidity-related risks of mortality, prognosis and risk of local recurrence, treatment benefit and toxicity in addition to patient preferences, priorities, and eventual social and financial issues (Biganzoli et al., 2012; Wildiers et al., 2007).

Controversial issues in managing patients with frailty due to either age or multi-morbidity which emerged at the ATTM are:

- 1) Deciding when a geriatric evaluation is indicated in frail patients;
- 2) Role of postoperative RT in pN0 patients receiving endocrine therapy (ET) after breast conserving surgery (BCS);
- 3) Selection of RT target volumes after BCS in pN1 patients: whole breast irradiation (WBI) vs WBI and regional nodes;
- 4) Indication for postoperative RT after mastectomy in pN1 patients;
- 5) Safety of hypo-fractionation for nodal irradiation;
- 6) Primary RT for inoperable patients.

3.1.1.1. Deciding when a geriatric evaluation is indicated in frail patients.

The benefits and risks of RT seem different in a frail population and therapy de-escalation may be indicated. Consequently, patients at high risk of falls, dementia, hospitalization and death, need to be identified.

Subjective evaluation tests (Biganzoli et al., 2012; Wildiers et al., 2007) include the Comprehensive Geriatric Assessment (CGA) which determines a frail person’s medical, psychological and functional capability to withstand a coordinated, integrated treatment plan and long-term follow-up (Parker et al., 2018; Overcash et al., 2019). Although recommended by the International Society of Geriatric Oncology (SIOG) (Wildiers et al., 2007), the CGA is too long and detailed for routine use in busy clinics. On the other hand, the Geriatric 8 (G8) Health Status Screening Tool consists of 8 questions that can be applied in approximately 10 minutes (Martinez-Tapia et al., 2017); the total score ranges from 17 (not at all impaired) to 0 (heavily impaired). For scores ≤ 14 , full geriatric evaluation with the CGA test is recommended (Overcash et al., 2019). A shorter version of the G8 with weight loss, cognition/mood, performance status, self-rated health status, poly-pharmacy and history of heart failure/coronary heart disease as

independent predictors was established as a more useful diagnostic tool (Martinez-Tapia et al., 2017; Soubeyran et al., 2014). The ATTM experts agreed the G8 questionnaire or its modified version should be used to assist in deciding whether RT is appropriate in frail, elderly patients.

3.1.1.2. Role of postoperative RT in pN0 patients receiving ET after BCS.

In older adult and/or frail patients, RT omission should be included as an option. Indeed, in older adults with a low risk of recurrence (e.g., small tumours, clear resection margins, negative axillary nodes, positive hormone-receptors, negative human epidermal growth factor receptor 2 -HER2-) RT omission is being extensively investigated, especially in the presence of ET (Hughes et al., 2013; Kim et al., 2019a; Fyles et al., 2004; Kunkler et al., 2015; Blamey et al., 2013). These studies, which were summarized in the 2018 ATTM report (Arenas et al., 2020), showed RT can be safely omitted in a selected low-risk sub-group who receive ET (Biganzoli et al., 2021; Burstein et al., 2021; Palumbo et al., 2021a). Ongoing studies, which are based on biomarkers and genomic profiling (Arenas et al., 2018, 2020; Franco et al., 2020), will better identify which patients are best candidates for RT omission after BCS.

As the alternative to RT is ET, its tolerance becomes crucial, since outside of clinical trials ET was often discontinued due to refusal and/or poor compliance or side-effects (Cortina et al., 2018). RT and ET are both suitable, as each was associated with an average annual 0.8% local recurrence rate in patients with T1N0 tumours, G1 or with good prognosis histology and no lympho-vascular invasion (Blamey et al., 2013). Consequently, post-operative RT alone might be considered for these patients.

The practice changing results of trials which explored hypo-fractionated schedules were discussed in depth in the 2018 ATTM report (Arenas et al., 2020). In 2020, ultra-hypo-fractionation was debated as an option for RT de-escalation in older adult/frail patients. The FAST Forward trial enrolled 4,096 patients with invasive breast carcinoma (pT1-3, pN0-1, M0) who were randomized to either 40 Gy (15 fractions), 27 Gy (5 fractions/1 week) or 26 Gy (5 fractions /1 week). The 5-year results showed the 5-fraction schedules were not inferior to the standard 15 fractions in terms of ipsilateral breast tumour relapse. Moderate or marked clinician-assessed side effects were reported as 9.9% with 40 Gy, 15.4% with 27 Gy and 11.9% with 26 Gy (Brunt et al., 2020a). Consequently, the authors recommended using the 26 Gy schedule which is now a standard of care option in the UK (Lewis et al., 2021). As it is particularly helpful for older adult/frail patients, it is likely to become the future standard in other countries. Alternatively, for frail patients a valid option is 28.5 Gy in 1 weekly fraction for 5 weeks (Brunt et al., 2020b).

Finally, RT may be de-escalated by reducing the irradiated volume. Level 1 evidence showed that PBI, as administered in hypo-fractionated or accelerated hypo-fractionated schedules, was not inferior to conventionally or hypo-fractionated WBI and was associated with a good toxicity profile (Polgar et al., 2013; Strnad et al., 2016; Schafer et al., 2018; Livi et al., 2015; Coles et al., 2017). PBI is delivered by means of multi-catheter interstitial brachytherapy, intra-cavitary brachytherapy, external beam RT (3D conformal or intensity-modulated) or intraoperative RT. Results depend on patient selection, dose distribution to the target, sparing of tissues at risk of toxicity and fractionation (Kaidar-Person et al., 2020). This topic was extensively analysed in the 2018 ATTM (Arenas et al., 2020). Since then, 26 Gy in 5 daily fractions for PBI has been strongly supported by the Royal College of Radiologists (RCR) Breast Radiotherapy Consensus update 2020 (Lewis et al., 2021) and is expected to be extended to other countries soon.

In summary, not only the number of fractions, but also treatment volumes are currently being reduced in selected sub-groups of patients. Innovative ultra-hypo-fractionated schedules appear safe and effective in the mid-term, providing satisfactory oncological outcomes. In older adult/frail patients all these options may serve to increase compliance

and reduce their hospital attendances for RT. Indeed, the need to minimize footfall within RT centres because of the COVID-19 pandemic has promoted the use of ultra-hypo-fractionation in some countries.

3.1.1.3. Selection of RT target volumes after BCS in pN1 patients: WBI vs

WBI and regional nodes. Regional node irradiation (RNI) should be considered for patients with 1-3 positive lymph nodes and adverse prognostic factors: extensive lympho-vascular invasion, a large, high-grade primary tumour with an unfavourable molecular profile (Recht et al., 2016). Its potential outcome in older adult/frail patients should be assessed in terms of reduced loco-regional recurrence (LRR), better overall survival (OS) vs RT-related risk of toxicity, life expectancy because of cancer and multi-morbidity and the chances of withstanding appropriate systemic therapy. For pN1 cases in the older adult, frail population, the clinical advantages of adding RNI to WBI may appear insufficient for routine use, especially when side effects are likely to be greater.

In attempts to satisfy patients' needs and reduce the discomfort that is linked to hospital attendances, hypo-fractionated RNI appears to be a feasible option (see below, issue 5).

3.1.1.4. Indication for postoperative RT after mastectomy in pN1 patients.

The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis showed that although post-mastectomy RT (PMRT) was associated with a proportional benefit, the absolute benefit changed in accordance with the absolute risk (EBCTCG, 2014). For example, a fit 65-year-old should be given PMRT since she has a good chance of living for another 10-20 years but PMRT may not be indicated if frailty and multi-morbidity change the risk benefit. Consequently, the indication to PMRT must be assessed individually by means of geriatric evaluation tests, considering tumour recurrence risk, life expectancy and comorbidities.

Few reports focused specifically on PMRT indications for intermediate-risk disease (i.e. pT1-T2N1) in older adults (Smith et al., 2006; Tseng et al., 2020; Shirvani et al., 2011; Smith et al., 2008). When patients were grouped as low-risk (pT1/T2 N0), intermediate-risk (pT1/T2 N1), or high-risk (pT3/T4 and/or N2/N3), SEER data analyses showed that, after a median follow-up of 6.2 years, PMRT was associated with a survival gain only for high-risk patients (Smith et al., 2006). These data are, however, flawed by the intrinsic bias of non-randomization and should be viewed with caution. For high-risk hormone receptor positive, HER2 negative patients, the phase III monarchE trial showed that adding abemaciclib to ET in the adjuvant setting reduced the risk of an invasive disease-free survival event by 30% and of distant relapse by 31%, at 3 years (Harbeck et al., 2021). The abemaciclib safety profile indicated about 5% higher incidence of grade >3 adverse events (mainly diarrhea and fatigue) in patients over 65 years compared with the younger age-group. Other, mainly low grade, events reported more frequently in the over 65 s included nausea, anemia, thrombocytopenia, and decreased appetite (Rugo et al., 2022). Studies are needed to evaluate the role of post-operative RT in patients who receive adjuvant abemaciclib-ET. Furthermore, the tumor biology responding best to adjuvant abemaciclib will be elucidated by the results of translational research investigating tissue and plasma samples from patients in the monarchE study (Johnston et al., 2020).

A hypo-fractionated schedule emerged as an option even though it was not specifically designed for delivering PMRT to older adult patients. Results of a phase 3 randomized trial reporting it was non-inferior to conventional fractionation and had a similar toxicity profile (Wang et al., 2019) were confirmed by a recent meta-analysis (Liu et al., 2020). Although large randomized clinical trials are advocated to confirm the efficacy and safety of hypo-fractionated PMRT in intermediate-risk older adults, the ATTM panel were of the view that current evidence showed it was safe for all age-groups (Yarnold, 2019).

Finally, the innovative ultra-hypo-fractionated schedules (27 Gy or

26 Gy in 5 fractions) were used for post-mastectomy chest wall RT in the randomized FAST-Forward trial (see above). Given the results, 26 Gy in 5 fractions over 1 week were very strongly supported by the RCR Breast Radiotherapy Consensus (Lewis et al., 2021).

3.1.1.5. Safety of hypo-fractionation for nodal irradiation. After a long debate about the risk of hypo-fractionated RNI-related toxicity in normal tissue (Liu et al., 2020; Haviland et al., 2018), 40 Gy delivered in 15 fractions has become standard of care in many countries. A retrospective analysis was conducted on 864 (14.7%) patients who were selected from a cohort of 5,861 in 3 prospective randomized UK Standardisation of Breast Radiotherapy (START) trials (Haviland et al., 2018). Patients had been treated with BCS (662) or mastectomy (202) and nodal volumes were different across the trials. At a median follow-up of 10 years, RT-related adverse side effects on arm and shoulder were assessed by physicians, patient responses to the EORTC QLQ-BR23 questionnaire and protocol-specific questions. No differences emerged in the hypo-fractionated and conventional schedules, suggesting hypo-fractionation to the regional nodes was safe. Since more adverse effects occurred after 13 fractions of 3.3 Gy, guidelines do not recommend this schedule. At the 2022 ESTRO Meeting the results of two phase III prospective randomized trials confirmed 40 Gy in 15 fractions was safe. Indeed, similar rates were observed of acute toxicity, lymphedema, shoulder motion and breast induration (Milo et al., 2022; Offersen et al., 2022). Similarly, the FAST Forward trial suggested in its interim analysis at 2-3 years' follow-up, that there were no differences in arm or shoulder adverse effects after 26 Gy in 5 fractions and the standard regimen (40 Gy in 15 fractions). Definitive assessment of non-inferiority will, however, be available only at the 5 year the analysis (Wheatley et al., 2022). The results of the trials in Table 4 are awaited.

3.1.1.6. Primary RT for inoperable patients. Frailty might be a contraindication to surgery, the gold standard of breast cancer treatment. In the Netherlands, the 98.7% rate of primary surgical treatment for patients aged 75 years and under dropped to 48.9% in patients aged 90

years and older. Additionally, 32% of patients over 75 years old refused surgery (Hamaker et al., 2013). In 446 patients over the age of 80, Helsinki University found that 3% had undergone surgery under local anesthesia, 10% did not have surgery and 75% in the non-surgical group received ET (Ojala et al., 2019). In fact, 40% of UK patients over 70 years old received ET as an alternative to surgery (Ward et al., 2018). In a series of 29 patients with diverse co-morbidities, who were inoperable or had refused surgery and/or had transport difficulties, the Institute Curie reported that, instead of surgery, they were given 32.5 Gy/5 fractions/5 weeks, followed by 13 Gy boost (two fractions of 6.5 Gy). Positive axillary lymph nodes, but not internal mammary or supraclavicular nodes, were also irradiated in five weekly fractions of 5.5 Gy. After a median follow-up of 93 months, the 95.8% loco-regional control rate was excellent (Chargari et al., 2010). A single-centre series reported that, in combination with ET, 115 patients (median age 83 years) were treated once weekly with hypo-fractionated RT (32.5 Gy in 5 fractions/5 weeks), followed by 1-3 fractions of 6.5 Gy to the tumour bed. The 5-year local progression-free rate was a good 78% (Courdi et al., 2006). Consequently, primary RT, with or without ET, emerged as a feasible alternative strategy for patients who are not candidates for surgery due to age, comorbidity, or refusal.

3.1.2. Current research studies

Although many on-going trials are evaluating RT in breast cancer patients with no upper age limit, very few enroll patients with WHO/ECOG performance status > 2 and even fewer focus specifically on the older adult and/or frail patients, anticipating eventually a subgroup analysis for this population.

Using key words "Older adult (65+)", "Interventional (Clinical Trial)", "Breast Cancer", "Elderly" and "Radiotherapy" a search was made for studies which were active or not yet open ("recruiting and not yet recruiting") and registered on "ClinicalTrial.gov". A total of 307 studies focused mainly on PBI or hypo-fractionated/accelerated WBI ± RNI, RT omission or replacement with ET. In the post-operative, intra-operative and pre-operative settings PBI has been, and is being,

Table 1
Studies on hypofractionation for whole breast/chest wall and regional node irradiation.

Trial	PI City, Country Accrual time	Population & study summary	Number of patients required	Primary endpoint
HYPOG-01 NCT03127995	Sofia Rivera, Paris, France. April 2017 – May 2021	Randomized. 40 Gy/ 15 fr/ 3 weeks (sequential boost 16 Gy/ 8 fr or SIB 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fr) vs 50 Gy/ 25 fr/ 5 weeks (sequential boost 16 Gy/ 8 fr or SIB 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fr) in BC with an indication for RNI	1265	Arm lymphedema at 5 and 10 years
Hypofractionated RT for Node-Positive BC NCT02700386	Christine Fisher, Colorado, USA. March 2016 - April 2021	Phase 2. 40.05 Gy/ 15 fr/ 3 weeks in BC with an indication for RNI, boost 10.68 Gy (2.67 Gy/ 4 fr)	112	Treatment-related adverse events as assessed by CTCAE version 4.03 up to 5 years
Hypofractionated RT for Patients With BC Receiving RNI NCT02958774	Shane Stecklein, Kansas, USA. Nov 2016 – April 2021	40.05 Gy/ 15 fr/ 3 weeks in BC with an indication for RNI, boost 10 Gy (2 Gy/ 5 fr)	389	Lymphedema rate at 1 year
The Skagen Trial 1 NCT02384733	Birgitte Offersen, Aarhus, Denmark. March 2015 – Feb 2020	Randomized. 40 Gy/ 15 fr/ 3 weeks vs 50 Gy/ 25 fr/ 5 weeks in BC with an indication for RNI, boost 2 dose levels, sequential: 16 Gy/8 fr and 10 Gy/5 fr, or SIB 63 Gy / 51.52 Gy / 28 fr, 57 Gy / 50 Gy / 25 fr, 52.2 Gy / 42.3 Gy / 18 fr, and 45.75 Gy / 40 Gy / 15 fr	2000	Arm lymphedema at 3 years
Conventional Versus Hypofractionated Adjuvant RT for Node Positive BC NCT02690636	Mahmoud Ellithy, Cairo, Egypt June 2016 – April 2021	Randomized. 42.56 Gy (2.66 Gy/day)/ 16 fr/ 5 fr per week (sequential boost 2.66 Gy x 4 fr) vs 50 Gy/ 25 fr/ 5 weeks (sequential boost 2 Gy x 5 fr) in BC with an indication for RNI	500	Locoregional recurrence at 5 years

PI: Principal Investigator; RT: Radiotherapy; BC: Breast Cancer; RNI: Regional Nodal Irradiation; fr: fraction; SIB: Simultaneous Integrated Boost; CTV: Clinical Tumor Volume.

Table 2

Open phase III trials (recruiting and not yet recruiting) on whole breast irradiation for elderly patients.

Trial	PI City, Country Accrual time	Population & study summary	Number of patients required	Primary endpoint
NeoRad NCT04261244	Christiane Matuschek, Duesseldorf, Germany. Jul 2020 - Dec 2030	Neoadjuvant Chemotherapy Followed by Preoperative vs postoperative RT in High-risk BC patients	1826	DFS at 6 to 10 years
PMRT-NNBC NCT02992574	Tabassum Wadasadawala. Delhi, India. May 2016 – Dec 2028	Post-mastectomy RT (40 Gy in 15 fr to the chest wall + supra clavicular fossa) vs no RT in high risk, node negative early BC patients	1022	DFS at 5 years
PRART NCT04175210	Silvia Formenti, New York, USA. Nov 2019 – Dec 2025	WBI (40 Gy) with a concomitant boost (48 Gy) to the tumor bed over 15 fr / 3 weeks vs 34/42 Gy in 10 fr / 2 weeks in stage 0 ductal carcinoma in situ (Tis (DCIS), stage T1-T2, lymph node negative (N0) BC patients	400	Rate of grade 3 or higher changes in breast cosmesis up to 5 years
Hypofractionated Post Mastectomy Radiation With Breast Reconstruction NCT03414970	Matthew Poppe, Salt Lake City, USA. Feb 2018 – Aug 2035	Hypofractionated vs normofractionated RT in patients with stage IIa-IIIa cancer who have undergone mastectomy.	880	Reconstruction complication rate at 2 years
HYPOSIB NCT02474641	Juergen Dunst, Kiel, Germany. Jun 2015 – Jun 2023	Hypofractionated RT with SIB vs normofractionated RT with SIB or sequential boost in patients with early BC	2324	PFS at 3 to 6 years

PI: Principal Investigator; RT: Radiotherapy; BC: Breast Cancer; DFS: Disease free survival; BCS: Breast Conserving Surgery; WBI: Whole Breast Irradiation; fr: fraction; PFS: Progression free survival; SIB: Simultaneous Integrated Boost.

Table 3

Open phase III trials (recruiting and not yet recruiting) on regional node irradiation for elderly patients.

Trial	PI Country Accrual time	Population & study summary	Number of patients required	Primary endpoint
RHEAL NCT04228991	Timothy Whelan, Ontario, Canada. Nov 2020 – Dec 2027	40 Gy/ 15 fr/ 3 weeks vs 26 Gy/ 5 fr/ 1 week to the breast and RN after BCS, or to the chest wall and RN following mastectomy in patients with node positive BC	588	Lymphedema at 3 years post randomization
HARVEST NCT03829553	Jiayi Chen, Shanghai, China. Feb 2019 – Dec 2028	Hypofractionated RT of (3 -4 weeks) vs conventional RT (5-6 weeks) using IMRT in BC patients with an indication for RNI following mastectomy or BCS	801	DMFS at 5 years
NCT01901094	Judy Boughey, Rochester, USA. Febr 2014 - Jan 2024	ALND and RT vs RT alone in patients with BC previously treated with chemotherapy and surgery	1660	Invasive BC recurrence-free interval up to 5 years

PI: Principal Investigator; RN: Regional Nodes (supraclavicular, axillary and internal mammary); RNI: Regional Nodes Irradiation; BC: Breast Cancer; TLNB: targeted lymph node biopsy; SNB: sentinel node biopsy; TAD: both TLDB+SNB; PST: primary systemic treatment; iDFS: Invasive disease-free survival; DMFS: Distant metastasis free survival; IMRT: intensity-modulated radiation therapy; BCS: Breast Conserving Surgery; ALND: Axillary Lymph Node Dissection.

extensively investigated in 43 mainly phase I or II trials. PBI is delivered by means of kV/MV photons, protons, electrons and 3D-conformal RT, IMRT or MR-LINAC. Treatment schedules vary in dosage, fractionation and overall times (1-10 fractions, 1-5 treatment days). Only 2/43 studies were identified when the search was narrowed down to phase III trials: the ongoing 2009-APBI trial (NCT01185132) and the EUROPA trial (NCT04134598) which was proposed at the 2018 ATTM (Arenas et al., 2020). Tables 1–3 summarize the trials which emerged after excluding PBI, supportive care, imaging, drug-testing, metastases or patients under 70 years old.

3.1.3. Proposed research strategy

The ATTM identified an unmet need in the management of breast cancer patients who are not eligible for surgery due to frailty or who refuse it after receiving full information. Despite this niche status, the ATTM proposed a phase III trial for cT1-T4 N0-3 M0 (de novo or local/

loco regional relapse) in patients with no upper age limit and WHO/ECOG performance status 0-3, who did not undergo surgery, independently of hormonal receptor and HER2 status. All candidates will be given standard treatment of choice (including best supportive care option) and will be randomized to ultra-hypo-fractionated RT (28.5 to 30 Gy/5 fractions/5weeks +/- boost or 26 Gy/5 fractions/1 week) or no RT, according to local guidelines. A cross-over is planned for local progression. The primary endpoint is QoL at 12 months. To identify predictive markers for RT response ancillary studies in collaboration with the Skagen group (a group of European physicians, who are investigating gains and risks from breast cancer RT), will focus on pre- and post- treatment biopsies and radiomics analysis. To encourage enrollment and facilitate data collection and analyses, the 2020 ATTM proposed an internal pilot study with 1-year recruitment and patient acceptance of randomization as go/no go criteria as well as a parallel “patient’s preference cohort” for ineligible patients.

Table 4
Ongoing clinical trials on stereotactic cranial radiotherapy and systemic therapy in oligometastatic breast cancer. Recruiting trials.

Trial	PI Country Accrual time	Population & study summary	Number of patients required	Primary endpoint
SRT BRAIN M1 BC NCT04061408	Jin Meng, China. 2019-21	HER2 + BC with brain M1 (N: 1-10) → SRT (3-5 fx of 8 Gy) +/- anti-HER2 (allowed)	170 Phase 2	At 2 years: intracranial LC, distant M1, PFS, OS, adverse events
LOCAL THERAPY BRAIN M1 HER2+ BC (Local HER-O) NCT02898727	Claire Phillips, Australia. 2017-20	HER2 + BC with brain M1 (N: 1-5) → neurosurgery and / or SRT (1fx 20 Gy to 3 fx (TD: 24 Gy)) + anti-HER2 (within 4 weeks of completion of brain M1 treatment)	50 Phase 2	At 1 year: LC, distant M1, OS, adverse events, neurocognitive function
T-DM1 + TMZ + SRT BRAIN M1 HER2+ BC NCT03190967	Alexandra Zimmer, USA. 2018-22	HER2+ BC with brain M1 → SRT, resection or WBRT + T-DM1 (anti-HER2) + TMZ (dose escalation)	125 Phase 1-2	MTD of TMZ used with T-DM1, adverse event, time at progression, median survival
SRT + PEMBROLIZUMAB BRAIN M1 BC NCT03449238	Silvia Formenti, USA. 2018-24	BC with brain M1 (N: 2-10, 5 mm - 4 cm) → Pembro (anti-PD-1) + SRT	41 Phase 1-2	Tumor response non-irradiated 8 weeks, abscopal response, OS
SRT + ATEZOLIZUMAB BRAIN M1 TNBC NCT03483012	Nancy U Lin, USA. 2018-21	TNBC with brain M1 (≤ 5) → Atezolizumab (anti-PD-L1) + SRT (inclusion: extracranial M1)	45 Phase 2	At 2 years: PFS, extracranial objective response, OS, toxicity, abscopal response
SRT + NIVOLUMAB BRAIN M1 BC NCT03807765	Kamran Ahmed, USA. 2019-22	BC with brain M1 (≤ 10, ≤ 4 cm) → Nivolumab (anti-PD-1) + SRT	12 Phase 1	DLT / Intracranial local / distant (3, 6, 12 months), PFS (1 year), OS (2 years)

PI: Principal Investigator; BC: breast cancer; fx: fraction; SRT: Stereotactic Radiation Therapy; M1: metastases; N: number; LC: local control; PFS: progression-free survival; OS: overall survival; TMZ: temozolamide; WBRT: whole brain radiotherapy; TNBC: triple negative BC; MTD: Maximum Tolerated Dose; DLT: Dose Limiting Toxicities; TNBC: Triple Negative Breast Cancer.

3.2. Topic 2. Stereotactic radiation therapy and systemic therapy in the management of oligometastatic disease

3.2.1. Current evidence and areas of contention

Oligometastatic disease was originally described in 1995 as an intermediate state between localized cancer and widespread metastases (Hellman and Weichselbaum, 1995). As detected on imaging studies, oligometastasis is identified as low-volume metastatic disease with up to 5 small lesions which are not necessarily in the same organ and which are potentially amenable to local treatment for complete remission (Cardoso et al., 2020). The ESTRO and the European Organisation for Research and Treatment of Cancer (EORTC) recently reached a consensus on clinical presentations of oligometastasis, suggesting it should not be considered as a single entity. A history of polymetastatic disease before diagnosis was the criterion which differentiated induced from genuine oligometastatic disease. Whether oligometastasis was diagnosed during a treatment-free interval or during active systemic

therapy and whether or not an oligometastatic lesion was progressing on current imaging led to the sub-classification of oligo-recurrence, oligo-progression and oligo-persistence, each with a different prognosis (Guckenberger et al., 2020) (Fig. 1).

Therapeutic approaches to these distinct clinical scenarios are based on a multi-disciplinary assessment and are usually multi-modal, including systemic therapies and local ablation. Lesion ablation, which can be achieved by means of stereotactic radiation therapy (SRT), is an excellent option for most patients as it is less invasive than surgery and can be used for several lesions at different sites (Cardoso et al., 2020; Corbin et al., 2013; Milano et al., 2008; Norihisa et al., 2008; Marazzi et al., 2020). Administered in hypo-fractionated schedules or in a single dose (radiosurgery, SRS), SRT is termed stereotactic body radiation therapy (SBRT) when delivered to extracranial lesions. Since advances in RT equipment and techniques allow most RT departments to adopt SRT safely, it is now commonly utilized for oligometastatic disease. As small volumes are irradiated with up to a maximum of 5 fractions, SRT




Fig. 1. Flowchart of classification of oligometastatic disease, modified from Guckenberger et al, Lancet Oncol 2020.

may interrupt systemic therapy briefly, or not at all, and may even be delivered concomitantly in some cases (Sharma et al., 2016).

Several phase II studies showed safety of SRT with favourable progression-free survival (PFS), and sometimes even OS rates (Gomez et al., 2019; Iyengar et al., 2018; Ost et al., 2018; Milano et al., 2019). After a median follow up of 25 months, the Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET) trial, which enrolled 99 patients with various cancers, each with up to 5 distant lesions, observed that the primary endpoint of OS significantly increased from 28 months to 41 months in the SBRT arm and PFS doubled from 6 months to 12 months; breast cancer cases were among the most represented ones (Palma et al., 2019).

Provided patient safety was ensured, the ATTM panel agreed that, with the aim of achieving a measurable clinical advantage, SRT might be administered to selected cases with more than 5 lesions and/or lesions larger than the 5 cm which is the usual cut-off for SRT (Lievens et al., 2020).

Controversial issues in SRT for oligometastatic breast cancer which emerged at the ATTM were:

1. Optimal therapeutic window, SRT dose and technique;
2. Optimal standardized imaging;
3. Predictors of early distant metastases and tumour progression;
4. Combination of SRT and systemic therapies.

3.2.1.1. Optimal therapeutic window, dose and technique. As the biomolecular mechanisms underlying metastatic spread are not yet fully understood, uncertainties persist about the optimal therapeutic window for intercepting the trajectory of metastasis evolution. Success relies on early detection and eradication of one or a few progenitor lesions with the potential for a massive poly-metastatic cascade and RT timing may have a major impact on disease-free-survival (DFS), PFS and perhaps even OS. For example, in oligoprogression, which is assumed to derive from clones that are resistant to the systemic therapy (Correa et al., 2016), the rationale for the therapeutic window is managing drug-resistant lesions. Although SRT use has been increasing over time, an international survey revealed a moderate agreement for applying it in oligometastatic breast cancer, as opposed to lung and colorectal cancers (Dagan et al., 2016) as SRT could potentially delay the start of systemic therapy, especially in those cases of triple negative or HER2 enriched tumours (Donovan et al., 2019).

No specific indications are available for doses and technical modalities according to the primary tumour and metastases localization. General recommendations are to deliver high biologically effective doses (BED) using high-precision RT equipment. In oligometastatic breast cancer, radiobiological data showed BED should be > 75 Gy (Kwapisz, 2019) as it correlated with higher OS (Hong et al., 2018) even though there are not enough pre-clinical or high-level clinical data to support one regimen over another (Wong et al., 2016). Furthermore, doses and fractionation schedules for brain and body SRT varied greatly across studies (Redmond et al., 2017).

3.2.1.2. Optimal standardized imaging. Although the imaging modality may influence the definition of oligo/polymetastatic disease, imaging workups for detecting oligometastases are not yet standardized, partly because guidelines provide no consensus. The general recommendation is to choose what best suits the disease site (e.g. magnetic resonance imaging for brain metastases). Additionally, lack of standardized interpretation may lead to bias, wrongful readings of imaging features, timing or response to treatment, as well as to poor estimates of tumour regression or progression etc., all of which may impact upon decisions about whether or not to administer or modify systemic therapy. Ultimately, the clinical outcome could be affected (deSouza et al., 2018).

These shortcomings may be overcome by collecting imaging data of

oligometastatic patients in databases such as the EORTC-ESTRO Oligo-care prospective registry trial (Guckenberger et al., 2020), so that future recommendations will be supported by clinical evidence. In this field, the use of large radiomic databases could be helpful.

3.2.1.3. Predictors of early distant metastases and tumour progression. In order to distinguish high-risk patients who will require personalized programs from those who are most likely to remain oligometastatic in the long-term (van de Vijver et al., 2002; Patel et al., 2019) predictors are needed to identify early distant metastasis occurrence and progression from oligometastases to polymetastases. It is unclear whether prognostic models stratifying patients into risk groups, on the basis of factors such as gender, performance status, DFS, can be applied to all tumour histologies or molecular subtypes (Van den Begin et al., 2019). In breast cancer better survival was associated with one metastatic lesion (vs 2-5), small tumour size, stable disease, disease regression before SRT and bone-only metastasis (Milano et al., 2019; Piroth et al., 2022). Indeed, the 5- and 10-year OS for patients with bone-only metastases was 83 and 75% vs 31 and 17%, respectively, for metastatic lesions at other sites. At the same time-points, patients with bone metastases had more freedom from widespread metastases (67% for both vs 30% and 15%, respectively). After 10 years local control of bone metastases was 100% vs 73% for other metastatic sites (Milano et al., 2019). The molecular subtype emerged as an independent prognostic predictor, with triple negative tumours being associated with worse survival (Possanzini and Greco, 2018).

With the aim of supplementing histological and clinical data, active investigations are focusing on tumour gene-expression profiling, single-cell sequencing, liquid biopsies, radiomic features (Cortinovis et al., 2021). In addition, microRNA expression was able to discriminate between post-SRT tendencies to remain oligometastatic or to progress to polymetastases (Lussier et al., 2011). In breast cancer research, “omic” technologies have not only enhanced the power of traditional models, but also revolutionized analysis of patient samples, making them an indispensable tool in translational studies. “Omic” studies have provided evidence that evolutionary processes in metastatic progression result in distinct biological entities that diverge greatly from the primary tumour (Winnard et al., 2020).

3.2.1.4. Combination of SRT and systemic therapies. In oligometastatic patients SRT can be concomitantly combined with various types of systemic therapy (i.e., chemotherapy, immune therapy, ET, targeted therapy) to optimize the therapeutic index of ionizing radiation; major concerns with the SRT/systemic therapy association are radiation-induced toxicity because of the potential synergic effect, combined toxicities and hypothetically an antagonist effect (Sharma et al., 2016; Rubino et al., 2022; Ingrosso et al., 2021; Palumbo et al., 2021b). For example, a drug may induce a cell cycle phase that is not responsive to RT (Cushman et al., 2018) and new targeted therapies may have unknown effects when combined with RT.

Very few safety and outcome data are available for concomitant SRT and systemic therapies in oligometastatic disease.

One study (Guénolé et al., 2020) recruited 95 oligometastatic patients with 188 lesions in different body sites (33 with breast cancer). SRT was administered concomitantly with diverse systemic therapies to 40% of patients without acute and late G3 toxicities.

Breast cancer is the leading cause of brain metastases, the risk of which is linked to the molecular subtype (Meattini et al., 2020). Some studies specifically analyzed outcomes in patients with HER-2 positive disease and brain metastases. In 84 patients with 487 brain metastases, 132 lesions (27%) were treated with SRS and concurrent lapatinib, and 355 (73%) with SRS alone. Concomitant SRS and lapatinib were associated with a significantly higher complete response rate (35% vs 11%, p=0.008), with no increase in the risk of grade 2+ radiation necrosis (1.0% with concurrent lapatinib vs 3.5% without, p= 0.27) (Kim et al.,

2019b). Confirming this finding, the incidence of symptomatic radionecrosis was low (3%) when SRS was associated with Trastuzumab Emtansine (T-DM1) (Mills et al., 2021). In another series of 126 patients with HER2-positive disease and 479 brain metastases, local failure was significantly less in 24 patients who received concomitant lapatinib and SRS (5.7% vs 15.1% ($p < 0.01$) at 12 months) (Parsai et al., 2020). Overall, these results suggest concomitant SRS and anti-HER2 therapy is safe and efficacious for local control.

Preclinical data demonstrated CDK4/6 inhibitors exerted radiosensitization effects by inhibiting DNA damage repair, enhancing apoptosis, blocking the cell cycle, inducing cellular senescence and promoting anti-tumor immunity (Yang et al., 2020). A retrospective study on 18 brain metastases reported that concurrent CDK4/6 inhibitors and SRT was well tolerated (Figura et al., 2019), and achieved 88% local control at 6 months follow-up which persisted at 12 months. In other reports palliative RT together with CDK4/6 inhibitors confirmed the safety and efficacy of the association (Kim et al., 2021; Ratosa et al., 2020). However, no conclusions can be drawn on the best combination due to the small cohorts and RT being delivered before, concurrently or after CDK4/6 inhibitors. Preclinical findings showed a greater antineoplastic effect when RT was delivered before CDK4/6 inhibitors compared with other treatment schedules. In order to confirm this result, the randomized CIMER (Combined IMMune Effects of therapies in metastatic ER-positive breast cancer) trial (NCT04563507) is recruiting women with newly diagnosed oligometastatic ER-positive breast cancer, who will be enrolled to receive either palbociclib/letrozole alone or preceded by SBRT to each metastatic lesion (Petroni et al., 2021).

After RT, spontaneous tumour regression was documented at sites distant to the irradiated volume. This immune-mediated phenomenon is called the “abscopal” effect (Demaria et al., 2004; Formenti and Demaria, 2009). It was observed in metastatic non small cell lung cancer. Pembrolizumab + RT increased the rate of out-of-field (abscopal) response rate to 41.7% vs 19.7% pembrolizumab alone and achieved an abscopal control rate of 65.3% vs 43.4% (Theelen et al., 2020). In breast oligometastatic disease, concomitant immunotherapy and RT may have a potentially synergic effect, particularly in the triple negative setting. In 19 patients with brain metastases SRT plus immunotherapy was compared with SRT alone. Concurrent immunotherapy was associated with better 1-year local control, OS, freedom from distant brain metastases but a significantly higher rate of radionecrosis (Guénolé et al., 2020). A phase II study assessed the efficacy and safety of pembrolizumab and SRT (30 Gy/ 5fr) on secondary lesions (Ho et al., 2020) in 17 patients. The overall response rate was 17.6% with 3 complete responders at 9 months follow-up and no G3 toxicity.

Predictive tumour (mutational burden, genomic mutation triggering radioresistance or radiosensitivity) and micro-environmental (T cell-inflamed gene expression profile) biomarkers are needed for predicting response to combined RT and immunotherapy. Markers of significant adverse immunoreactions are also needed (Muraro et al., 2017).

To reduce skeletal morbidity linked to both cancer and its treatments in breast cancer patients with bone metastases, whether symptomatic or not, guidelines recommend administering denosumab or zoledronate (Coleman et al., 2021) which reduced the risk of fracture, stimulated osteoclastic remodeling and increased immune response and radiosensitivity in preclinical and clinical studies. In a multicenter phase 1 study of 30 patients, (10% with breast cancer) 49 vertebral metastases received zoledronate combined with SRT (27 Gy in 3 fractions). Only one vertebral collapse was observed. Overall, the zoledronate-SRT combination was well tolerated, effectively relieved pain, and achieved good local tumor control with no late neurologic adverse effects (Pichon et al., 2016).

The ATTM panel concluded that more clinical, biomolecular and microenvironmental data should be collected, pooled and analysed to provide definitive evidence of safety and outcomes after combined SRT and systemic therapy.

3.2.2. Ongoing clinical studies

Several ongoing clinical trials are exploring the roles of SRT (as delivered in a single fraction or with hypo-fractionated schedules to brain or extracranial metastases), and systemic therapy in the management of oligometastatic breast cancer with the most common primary endpoints being PFS, OS and toxicity (Cushman et al., 2018; Makhlin and Fox, 2020). Table 4 lists ongoing phase 1-2 clinical trials using brain SRT with systemic therapies. Inclusion criteria are up to 10 brain metastases, each of them up to 4 cm in diameter, and eventually extracranial metastases. Table 5 lists phase 1-2 and 3 ongoing trials of SBRT combined with systemic therapies in breast cancer patients with a maximum of five metastases, up to 10 cm in size. The multicenter STEREO-SEIN (NCT02089100), a key phase 3 trial, aims at assessing SRT effectiveness in de novo oligometastatic disease by evaluating PFS, local failure and OS rates. Inclusion criteria are up to 5 metastatic lesions (measurable or not). Measurable lesions have to be ≤ 10 cm in size (≤ 7 cm for hepatic metastases). All lesions will be treated with SRT and compared with a systemic therapy arm delivering RT only for palliation. The “NRG BR002”, a randomized phase II/III trial, will enroll newly oligometastatic breast cancer patients with ≤ 4 non-cranial lesions that did not progress after up to 12 months first line systemic therapy. Patients will be randomized to standard of care therapy with or without SRT and/or surgical resection of all metastatic sites. Similarly, STEREO-OS (NCT03143322), a phase 3 trial for breast, lung and prostate cancer patients with 1-3 bone metastases, will assess systemic therapy combined with SRT in different fractionations (9 Gy x 7 fractions or 7 Gy x 5 fractions) vs systemic therapy alone with palliative RT.

3.2.3. Proposed RT research strategy

The ATTM panel identified assessment of the SRT association with systemic therapy as a main unmet need in oligometastatic breast cancer. Two main research areas emerged:

- (A) To evaluate RT and new targeted therapies in the oligometastatic setting the ATTM proposed setting up a multi-centre study for retrospective and prospective analysis of breast cancer patients who received CDK 4/6 inhibitors \pm sequential or concomitant RT, not necessarily SRT. Endpoints are local control, PFS, OS and treatment related toxicities.
- (B) Sequential use of SRT and immunotherapy with atezolizumab to improve outcomes in triple negative, PDL1+ oligometastatic patients. The RATEO trial will be a prospective observational study on the effects and toxicity of SRT to all oligometastatic sites before ATEzolizumab + nab-paclitaxel. The primary endpoint is toxicity; secondary end-points are PFS and OS.

3.3. Topic 3. Contralateral breast tumour prevention in BCRA-mutated patients

3.3.1. Current evidence and areas of contention

The main promoters of breast carcinogenesis are the tumour suppressor genes, BRCA1 and BRCA2 although low penetrance genes like PALB2, BARD1, RAD51C, RAD51D, ATM and CHEK2 were linked to breast cancer and correlated with it and its different sub-types in two large case control studies of women from the U.S., Europe and Asia (Sauthor1\$ et al., 2021; Hu et al., 2021).

Even though BRCA1 and BRCA2 confer cancer susceptibility with one germline defective chromosome copy, two defective alleles are needed for malignant transformation. BRCA1 and BRCA2 encode proteins that are involved in DNA repair via homologous recombination, cell cycle control via checkpoint modulation and maintenance of overall genomic stability (Brose et al., 2002; Lakhani et al., 1998; Paluch-Shimon and Evron, 2019; Pierce and Haffty, 2011; Venkitaraman, 2002). BRCA1 mutated breast cancers are typically high-grade tumours, with a high mitotic index, p53 over-expression and often have the triple-negative phenotype. BRCA2-mutated breast cancers are

Table 5
Ongoing clinical trials on stereotactic extracranial radiotherapy and systemic therapy in oligometastatic breast cancer. Recruiting trials.

Trial	PI Country Accrual time	Population & study summary	Number of patients required	Primary endpoint
SBRT BC (STEREO-SEIN) NCT02089100	Celine Bourgier, France. 2014-23	HHRR+ BC ≤ 5 M1 lesions, ≤10 cm (for hepatic M1 ≤ 7 cm) → SBRT vs no therapy except for palliation. Beginning ST before 2 and 7 days after SBRT completion	280 Phase 3	At 3 years: LC, PFS and OS
SBRT FOR SPINAL M1 IN FAVORITE TUMORS NCT03392233	Ming Ye, China. 2017-27	BC, prostate, lung → SBRT spinal M1 (3 fx 24 Gy or 3 fx 30 Gy)	100 Phase 2	The rate of relieve pain (1 week after SBRT to 2 years later), toxicity
STANDARD OF CARE +/- SBRT +/- SURGERY M1 BC NCT02364557	Steven Chmura, USA. 2014-22	BC ≤ 4 M1 lesions, ≤ 5 cm → Standard of care (planned ST) vs SBRT (1-3-5 fx) or surgery + ST	402 Phase 2-3	PFS (3 years), OS (8 years), new M1, adverse effects, CTC blood, ctDNA plasma
STANDARD OF CARE +/- SBRT FOR M1 CANCER NCT03808337	Jonathan Yang, USA. 2019-22	BC, lung, 1-5 M1 → Standard of care (ST, targeted therapies, HT) +/- SBRT (For lung: 5 fx 50 Gy, 4 fx 48 Gy, 3 fx 54 Gy / Others: 3 fx 27-30 Gy, Bone: 1 fx 24 Gy)	142 Phase 2	Up to 2 years: PFS, OS
CORE STUDY NCT02759783	Vincent Khoo, UK. 2016-19	BC, prostate, NSCLC, ≤ 3 M1 → Standard of care +/- SBRT	245 Phase 2-3	At 3 years: PFS
SBRT vs STANDARD OF CARE BREAST AND LUNG M1 NCT03808662	C. Jillian Tsai, USA. 2019-22	BC, lung, 1-5M1 → Standard of care vs SBRT (3 fx of 9-10 Gy, 5 fx of 10 Gy)	160 Phase 2	PFS, OS
SBRT LUNG LIVER M1 BC NCT02581670	Fiorenza De Rose, Italy. 2015-20	BC lung and liver M1 < 5 M1 < 5 cm → SBRT (VMAT)	40 Phase 2	Toxicity, LC (2 years), PFS, OS, QoL
INTERVENTION TO LIVER LUNG M1 BC (IMET) NCT02251353	Hasan Karalink, Turkey. 2014-22	BC lung and / or liver M1 → resection and / or radiofrequency ablation, Transcatheter arterial chemoembolization, CyberKnife SBRT vs no intervention	300 Cohort	At 3 years: OS, PFS, morbidity due to treatment modality (6 months)
STANDARD TREATMENT +/- SBRT SOLID TUMORS BONE M1 (STEREO-OS) NCT03143322	Sebastian Thureau, France. 2018-22	BC, prostate, lung, 1-3 bone M1 → Standard treatment + SBRT (7 fx of 9 Gy, 5 fx of 7 Gy) vs Standard treatment	196 Phase 3	At 1, 2 and 3 year: PFS, LC, OS, toxicities, QoL, cost utility
SBRT + ATEZOLIZUMAB TNBC M1 (AZTEC) NCT03464942	Sherene Loi, Australia. 2018-22	TNBC 1-4 M1 with at least 1 Untreated → SBRT (1 fx 20 Gy or 3 fx 24 Gy) + Atezolizumab	52 Phase 2	At 2 years: PFS, objective response, adverse events, OS
ANTI-VACCINATION WITH FIT3L, RT AND POLY-IJCLC NCT03789097	Joshua Brody, USA. 2019-23	BC, NHL, HN → Pembro + Fit3L + SBRT + Poly-IJCLC	56 Phase 1-2	DLT, overall response rate (6 months)
SBRT AND ONCOLYTIC VIRUS BEFORE PEMBROLIZUMAB FOR M1 TNBC AND NSCLC NCT03004183	Jenny Chang, USA. 2017-22	BC, NSCLC → ADV/HSV-tk + Valacyclovir + SBRT + Pembro	57 Phase 1-2	At 30 days: overall response rate, duration of response, OS rate, PFS, adverse events, change in immunohistochemical expression

PI: Principal investigator; BC: breast cancer; SBRT: Stereotactic Body Radiotherapy; HHRR: hormonal receptors; M1: metastases; ST: systemic treatment; HT: hormonal treatment; LC: local control; PFS: progression-free-survival; OS: overall survival; QoL: quality of life; CTC: circulating tumor cells; ctDNA: circulating tumor DNA; TNBC: triple negative BC; DLT: Dose Limiting Toxicities; VMAT: Volumetric Modulated Arch Therapy; NHL: Non Hodgkin Lymphoma; HN: Head and Neck cancer; NSCLC: non-small cell lung cancer.

more likely to be estrogen and progesterone receptor positive (Lakhani et al., 1998). Furthermore, in the Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH), the BRCA mutation was more common in women with triple-negative disease (136/558 (24%) (Copson et al., 2018).

Germline mutations in BRCA1 or BRCA2 account for 3%-5% of breast cancers; prevalence is higher in patients < 50 years old, particularly BRCA1 carriers, who are at high risk of recurrent ipsilateral and contralateral breast cancer (Stjepanovic et al., 2020; Carbine et al., 2018), as well as ovarian cancer (Heemskerk-Gerritsen et al., 2019; Hartmann et al., 2001; Meijers-Heijboer et al., 2001), having an overall lifetime risk of up to 80% and 40%, respectively (Brose et al., 2002). BRCA1 is associated with a 53% lifetime risk (20-year risk 40%) for contralateral cancer development and BRCA2 with a 65% risk (20-year risk 26%) (Pierce and Haffty, 2011; Evron et al., 2014). The BRCA

mutation was identified in 338/2,733 young women (12%) in the POSH cohort. At a median follow up of 8.2 years contralateral breast cancer was identified in 151 (6%) patients: 18% of BRCA1 carriers, 12% of BRCA2 carriers and 4% patients with no BRCA mutation. Median time to contralateral breast cancer diagnosis was 2.7-3 years (Copson et al., 2018). Although prognosis was reported to be worse in women with BRCA mutations than in patients with sporadic breast cancer, survival rates were similar in recent studies (Goodwin et al., 2012; Huzarski et al., 2013).

Controversial issues in managing BRCA1/2-mutated early breast cancer which emerged at the ATTM were:

1. Outcome after mastectomy and BCS ± RT (BCT);
2. BCT in BRCA1/2 carriers and non-carriers;
3. Risk-reducing contralateral mastectomy;

4. RT as prophylactic contralateral breast risk-reduction approach.

3.3.1.1. Outcome after mastectomy and BCT. In BRCA carriers with early breast cancer, mastectomy and axillary node assessment are often recommended even though no prospective randomised studies have compared mastectomy and BCS. In the POSH cohort of 3,024 breast cancer patients ≤ 40 years old, no differences emerged in distant disease-free survival or OS following mastectomy (1,464) or BCS (1,395) after adjusting for prognostic features (especially, T and N stage and hormone receptor status) (Maishman et al., 2017). A recent review by Vallard et al. noted that short-term local control, metastasis-free survival and OS were equivalent after mastectomy and BCT in BRCA carriers. Long-term local control remains a controversial issue as all long-term studies were retrospective, with few patients and infrequent use of the systemic therapies that are standard of care today (Vallard et al., 2019). Another metanalysis showed increased risk of locoregional recurrence after BCT while the risk of contralateral breast cancer, disease recurrence, disease-specific recurrence and death were equivalent after BCT and mastectomy (Davey et al., 2021). To manage hereditary breast cancer an expert panel from the American Societies of Clinical Oncology (ASCO), Radiation Oncology (ASTRO) and Surgical Oncology (SSO) suggested that “Germline BRCA status should not preclude a patient with newly diagnosed breast cancer otherwise eligible for breast conservation from receiving BCT” (Tung et al., 2020). In our view, concurring with others, BRCA mutation carriers should be appropriately counselled about both surgical options so as to achieve the best possible outcome.

3.3.1.2. BCT in BRCA1/2 carriers and non-carriers. After BCT, ipsilateral breast tumour recurrence (IBTR) appeared to be a new cancer rather than a true IBTR as its onset tended to be more than 5 years later, in another location to the primary tumour site with sometimes different histology (Morrow, 2022). In older series the incidence of IBTR was higher in BRCA1/2 carriers than in sporadic cases (Lakhani et al., 1998). Recent results suggested it was similar, especially if carriers had also undergone bilateral salpingo-oophorectomy (BSO) and received adjuvant systemic therapy (van den Broek et al., 2019; Bernier and Poortmans, 2015; Kirova et al., 2010, 2005; Pierce et al., 2006, 2010). Pierce et al. reported no significant difference in 10- and 15-year IBTR rates in BRCA1/2 carriers and sporadic cases and identified factors that reduced the risk of IBTR as older age, chemotherapy and BSO (Pierce et al., 2006). In a Dutch cohort of breast cancer patients, about half of whom underwent BCT, the 10-year cumulative risk of IBTR was 7.3% in BRCA1 carriers and 7.9% in non-carriers. The authors concluded that BCT may be offered to BRCA mutation carriers undergoing therapy for unilateral breast cancer (van den Broek et al., 2019). In a meta-analysis of 10 studies Valachis et al., reported that BCT did not increase the risk of IBTR in carriers and indicated that RT was equally effective in both groups. When analyses were restricted to studies with a follow-up of at least 7 years (five studies, with a total 1,634 patients), the local recurrence rate emerged as significantly worse in carriers (24% carriers vs 16% non-carriers; $p < 0.003$) (Valachis et al., 2014). Clinical data suggested RT-related toxicity profiles were similar in BRCA1/2 mutated patients and sporadic cases (Shanley et al., 2006). A retrospective cohort study by Pierce et al. observed similar rates of acute or chronic toxicities in the skin, subcutaneous tissue, lung and bone, according to RTOG acute morbidity scoring criteria (Pierce et al., 2000).

In BRCA mutation carriers the 10-year cumulative risk of contralateral breast cancer was 23.9% when diagnosed before 41 years of age, dropping to 12.6% when diagnosed in the 41-49 age-group (van den Broek et al., 2016). Contralateral breast cancer risks were 25%-30% over 10 years and more than 40% over 15 years, compared with 3% and 7%, respectively, in non-carriers (Pierce et al., 2010; Metcalfe et al., 2004). Women with BRCA1 mutations had a significantly higher cumulative

risk 20 years after breast cancer diagnosis than those with BRCA2 mutations (40% and 26%, respectively; $p = 0.001$) (Kuchenbaecker et al., 2017). The risk of contralateral breast cancer exceeded 40% in the entire series of 655 BRCA mutation carriers with early breast cancer who received BCS (302/655) or mastectomy (353/655). It was not significantly different whether postoperative RT was administered or not, suggesting no added risk from scatter RT at 10 and 15 years (Pierce et al., 2010). Likewise, no increase in radiation-related secondary malignancies, such as thyroid tumours, was observed in a large cohort of 230 BRCA mutation carriers with early breast cancer who were treated with breast and/or chest wall RT, with or without regional node irradiation (Schlosser et al., 2020). A high, long-term risk of developing contralateral primary breast cancer was initially reported in women < 40 years of age who received a radiation dose > 1.0 Gy to the contralateral breast (Stovall et al., 2008; Hooning et al., 2008). In the WECARE cohorts, however, analysis of BRCA-mutation carriers showed that the mutation itself, rather than the radiation dose, was associated with greater risk of contralateral breast cancer (RR 4.5) (Bernstein et al., 2013).

3.3.1.3. Risk-reducing mastectomy. Current recommendations for BRCA mutation carriers advocate an intensified screening programme, BSO (to reduce the risk of breast and ovarian cancer) (Elezaby et al., 2019) and consideration of bilateral risk-reducing mastectomy (Rebbeck et al., 2004). In a large Dutch prospective series with a median follow up of > 10 years, bilateral risk-reducing mastectomy was associated with lower mortality than surveillance only for BRCA1 mutation carriers and with similar BC-specific survival for BRCA2 mutation carriers. Most women in both mutational groups had opted for prophylactic BSO and more women who chose bilateral risk-reducing mastectomy rather than surveillance underwent BSO (Heemskerk-Gerritsen et al., 2019).

In BRCA1/2 carriers Rebbeck et al. found risk-reducing mastectomy decreased the risk of primary breast cancer by 90%; combining mastectomy with oophorectomy led to a 95% reduction (Rebbeck et al., 2004). Since risk-reducing mastectomy lowered the risk of contralateral breast cancer in BRCA mutation carriers, ASCO, ASTRO and SSO recommended offering it to all carriers who have been or are being treated with unilateral mastectomy (Tung et al., 2020). Despite this, evidence for improved survival was insufficient and a recent Cochrane analysis pointed out that risk-reducing mastectomy had not been evaluated in prospective randomized studies (Carbine et al., 2018). Furthermore, it could incur mutilation-related psychological costs as, fearing its effect on their body image, sexuality and sensation, many patients seek alternative preventive measures (Robson et al., 1998; Metcalfe et al., 2019). All these implications pose a difficult dilemma for many patients who may already be confused (Sacks and Morrow, 2020). Furthermore, the significantly high risk of ovarian cancer and its high mortality rate have to be kept in mind when decision making with women carrying BRCA mutations, particularly BRCA1.

Oophorectomy, chemotherapy and ET with tamoxifen all significantly decreased the risk of contralateral breast cancer after treatment of the primary tumour; increasing age was another factor linked with a lower risk (Valachis et al., 2014; Metcalfe et al., 2004). Overall, these findings support individualized counselling for patients with each BRCA mutation type.

3.3.1.4. RT as prophylactic contralateral breast risk-reduction approach. Israel has a relatively large cohort of BRCA mutation carriers, as around 20% of Israeli breast cancer patients are mutation carriers (Manchanda et al., 2019). From 2007 to 2017, 162 BRCA mutation carriers with unilateral breast cancer were enrolled in a phase II non-randomized trial (NCT00496288), offering standard loco-regional treatment of the primary breast cancer and the option of prophylactic contralateral breast irradiation instead of contralateral risk-reducing mastectomy. At a median follow-up of 5 years, contralateral breast irradiation significantly

reduced the risk of subsequent contralateral breast cancer (Evron et al., 2019). Compared with the diseased breast, early radiation-related toxicities were not increased and there were no major grade 3-4 acute events. Late toxicity rates were similar but one patient developed radiation-associated sarcoma in the prophylactically irradiated breast. Even though follow up will continue to assess late events (Poortmans and Kaidar-Person, 2019), present data justify further studies investigating the potential role of bilateral irradiation in BRCA carriers (Narod, 2019).

3.3.2. Ongoing clinical studies

To the best of our knowledge, only one ongoing clinical trial is evaluating contralateral risk-reducing RT in hereditary breast cancer patients (NCT00496288 from Assaf-Harofeh Medical Center). Five trials registered on Clinicaltrials.gov are focusing on psychological distress linked to risk-reducing mastectomy (NCT03061175; NCT02918474; NCT02263014; NCT00579007; NCT00555503).

3.3.3. Research proposal

The genetic risk of breast cancer has recently assumed a central role and recent findings justify growing interest in the issues of how BRCA mutated patients should be treated and whether RT protocols should be tailored to this genetic make-up. On the one hand, referring women for bilateral mastectomy is a major commitment for patients and health service organization and resources while on the other, prophylactic RT might be a valid alternative option for reducing the risk of contralateral cancer. The ATTM panel consequently propose an international, multi-centre randomized phase III trial of prophylactic contralateral breast irradiation for BRCA mutation carriers who have declined contralateral risk-reducing mastectomy and are candidates for ipsilateral RT (breast or chest wall ± RNI) as part of their standard loco-regional treatment for early breast cancer.

Prophylactic contralateral breast irradiation (40 Gy/15 fr) in breast cancer patients bearing BRCA 1/2 mutations is expected to significantly reduce the risk of contralateral breast cancer within 10 years follow up. All eligible patients who are candidates for adjuvant RT will be given ipsilateral irradiation and will be randomized to receive or not contralateral breast irradiation. Ipsilateral and contralateral RT will be delivered concomitantly. The primary endpoint will be 10-year contralateral breast cancer free survival. Secondary endpoints will be toxicity and contralateral breast radiation-related complications, QoL, 10-year DFS and OS.

4. Conclusions

The ATTM, with its experts on breast cancer who brainstorm on RT-related hot topics, is attracting more and more attention worldwide in the scientific community. This 2020 ATTM white paper reports in-depth analysis of the state of the art, open questions (grey areas and controversies) in breast cancer RT and lively discussion on how to confront them when evidence-based data or expert opinions are insufficient to guide clinical decision-making. Furthermore, the ATTM assessment of the design and end-points of on-going studies is expected to lead to ideas for innovative investigations. All the authors of this white paper sincerely hope even more young radiation and clinical oncologists will attend future ATTMs so they are stimulated to become involved in research projects and improve their critical skills when faced with controversial clinical cases.

Role of the funding source

The research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Legend to the Fig. 1: Flowchart of classification of oligometastatic disease, modified from Guckenberger et al., Lancet Oncol 2020

Conflict of interest

Dr Maria Cristina Leonardi received speaker fee from Accuray Inc. Prof. Icro Meattini reports occasional advisory boards supported by Eli Lilly, Novartis, Pfizer, and Roche, outside the submitted work. Prof. Philip Poortmans report a medical advisor role for Sordina IORT Technologies S.p.A. outside the submitted work. All other authors declare that they have no conflict of interest. All the Authors made substantial contribution to the conception and design of the study, data acquisition or analysis and interpretation, drafting the article or revising it critically. All have approved the final version which I am submitting. Our work has not been published previously and the manuscript has not been submitted elsewhere.

References

- Aristei, C., Kaidar-Person, O., Arenas, M., Coles, C., Offersen, B.V., Bourcier, C., et al., 2016. The 2016 Assisi Think Tank Meeting on breast cancer: white paper. *Breast Cancer Res Treat.* 160, 211–221. <https://doi.org/10.1007/s10549-016-3998-2>.
- Arenas M., Selek U., Kaidar-Person O., Perrucci E., Montero Luis A., Boersma L., et al. The 2018a assisi think tank meeting on breast cancer: International expert panel white paper. *Crit Rev Oncol Hematol.* 2020;151:102967. doi.org/10.1016/j.critrevonc.2020.102967.
- Valentini, V., Marijnen, C., Beets, G., Bujko, K., De Bari, B., Cervantes, A., et al., 2020. The 2017 Assisi Think Tank Meeting on rectal cancer: a positioning paper. *Radiother. Oncol.* 142, 6–16. <https://doi.org/10.1016/j.radonc.2019.07.001>.
- Johnson, H.M., Irish, W., Muzaffar, M., Vohra, N.A., Wong, J.H., 2019. Quantifying the relationship between age at diagnosis and breast cancer-specific mortality. *Breast Cancer Res. Treat.* 177, 713–722.
- Harbeck, N., Penault-Llorca, F., Cortes, J., Gnani, M., Houssami, N., Poortmans, P., et al., 2019. Breast cancer. *Nat. Rev. Dis. Prim.* 5, 66 doi.org/10.1038/s41572-019-0111-2.
- Telli, M.L., Gradishar, W.J., Ward, J.H., 2019. NCCN guidelines updates: breast cancer. *J. Natl. Compr. Canc Netw.* 17, 552–555.
- Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., et al., 2012. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). *Lancet Oncol.* 13, e148–e160.
- Martin, M., Collignon, J., Rorive, A., André, C., Bourhaba, M., Allepaerts, S., et al., 2011. Breast cancer in the elderly patient. *Rev. Med. Liege* 66, 400–408.
- Wildiers, H., Kunkler, I., Biganzoli, L., Fracheboud, J., Vlastos, G., Bernard-Marty, C., et al., 2007. Management of breast cancer in elderly individuals: recommendations of the international society of geriatric oncology. *Lancet Oncol.* 8, 1101–1115.
- Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., et al., 2001. Frailty in older adults: evidence for a phenotype. *J. Gerontol. Med. Sci.* 56A, M146–M156.
- Mitnitski, A.B., Mogilner, A.J., Rockwood, K., 2001. Accumulation of deficits as a proxy measure of aging. *TheScientific World* 1, 323–336.
- Parker, S.G., McCue, P., Phelps, K., McCleod, A., Arora, S., Nockels, K., et al., 2018. What is comprehensive geriatric assessment (CGA)? An umbrella review. *Age Ageing* 47, 149–155.
- Overcash, J., Ford, N., Kress, E., Ubbing, C., Williams, N., 2019. Comprehensive geriatric assessment as a versatile tool to enhance the care of the older person diagnosed with cancer. *Geriatrics* 4, 39.
- Martinez-Tapia, C., Paillaud, E., Liu, E., Tournigand, C., Ibrahim, R., Fossey-Diaz, V., et al., 2017. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. *Eur. J. Cancer* 83, 211–219.
- Soubeyran, P., Bellera, C., Goyard, J., Heitz, D., Curé, H., Rousselot, H., et al., 2014. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter Cohort study. *PLoS One* 9, e115060.
- Hughes, K.S., Schnaper, L.A., Bellon, J.R., Cirrincione, C.T., Berry, D.A., McCormick, B., et al., 2013. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. *J. Clin. Oncol.* 31, 2382–2387. <https://doi.org/10.1200/JCO.2012.45.2615>.
- Kim, Y.J., Shin, K.H., Kim, K., 2019a. Omitting adjuvant radiotherapy for hormone receptor-positive early-stage breast cancer in old age: a propensity score matched SEER analysis. *Cancer Res. Treat.* 51, 326–336.
- Fyles, A.W., McCready, D.R., Manchul, L.A., Trudeau, M.E., Merante, P., Pintilie, M., et al., 2004. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. *N Eng. J. Med* 351, 963–970.
- Kunkler, I.H., Williams, L.J., Jack, W.J., Cameron, D.A., Dixon, J.M., 2015. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *Lancet Oncol.* 16, 266–273. [https://doi.org/10.1016/S1470-2045\(14\)71221-5](https://doi.org/10.1016/S1470-2045(14)71221-5).
- Blamey, R.W., Bates, T., Chetty, U., Duffy, S.W., Ellis, I.O., George, D., et al., 2013. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British association of surgical oncology (BASO) II trial. *Eur. J. Cancer* 49, 2294–2302. <https://doi.org/10.1016/j.ejca.2013.02.031>.
- Biganzoli, L., Battisti, N.M.L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I.H., et al., 2021. Updated recommendations regarding the management of older patients

- with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). *Lancet Oncol.* 22, e327–e340. [https://doi.org/10.1016/S1470-2045\(20\)30741-5](https://doi.org/10.1016/S1470-2045(20)30741-5).
- Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., et al., 2021. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann. Oncol.* 32, 1216–1235. <https://doi.org/10.1016/j.annonc.2021.06.023>.
- Palumbo, I., Borghesi, S., Gregucci, F., Falivene, S., Fontana, A., Aristei, C., et al., 2021a. Omission of adjuvant radiotherapy for older adults with early-stage breast cancer particularly in the COVID era: a literature review (on the behalf of Italian association of radiotherapy and clinical oncology). *J. Geriatr. Oncol.* 12, 1130–1135. <https://doi.org/10.1016/j.jgo.2021.05.008>.
- Arenas, M., Nguyen, N., Franco, P., Sele, U., Roviro, A., Sabater, S., 2018. Oncology: management of elderly cancer patients. *Biomed. Res. Int.* 2018, 7362585.
- Franco, P., De Rose, F., De Santis, M.C., Pasinetti, N., Lancellotta, V., Meduri, B., et al., 2020. Clinical Oncology Breast Cancer Group (COBCG) Investigators. Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine. *Clin. Transl. Radiat. Oncol.* 21, 112–119.
- Cortina, C.S., Agarwal, S., Mulder, L.L., Poirier, J., Rao, R., Ansell, D.A., et al., 2018. Are providers and patients following hormonal therapy guidelines for patients over the age of 70? The influence of CALGB 9343. *Clin. Breast Cancer* 18, e1289–e1292.
- Brunt, M.A., Duncan, A., Haviland, J.S., Wheatley, D.A., Sydenham, M.A., Alhasso, A., Bloomfield, D.J., Charlie Chan, C., et al., 2020a. On behalf of the Group F-FM. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. *Lancet* 395, 1613–1626.
- Lewis, P., Brunt, A.M., Coles, C., Griffin, S., Locke, I., and Roques, T. on behalf of the Breast Radiotherapy Consensus Working Group. Moving forward fast with FAST-Forward. *Clin Oncol (R Coll Radiol)*. 33:427–429. DOI: 10.1016/j.clon.2021.04.007.
- Brunt, M.A., Haviland, J.S., Sydenham, M., Agrawal, R.K., Algurafi, H., Alhasso, A., et al., 2020b. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. *J. Clin. Oncol.* 38, 3261–3272.
- Polgar, C., Fodor, J., Major, T., Sulyok, Z., Kasler, M., 2013. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. *Radiother. Oncol.* 108, 197–202. <https://doi.org/10.1016/j.radonc.2013.05.008>.
- Strnad, V., Ott, O.J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., et al., 2016. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. *Lancet* 387, 229–238. [https://doi.org/10.1016/S0140-6736\(15\)00471-7](https://doi.org/10.1016/S0140-6736(15)00471-7).
- Schafer, R., Strnad, V., Polgar, C., Uter, W., Hildebrandt, G., Ott, O.J., et al., 2018. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. *Lancet Oncol.* 19, 834–844.
- Livi, L., Meattini, I., Marrazzo, L., Simontacchi, G., Pallotta, S., Saieva, C., et al., 2015. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. *Eur. J. Cancer* 51, 451–463. <https://doi.org/10.1016/j.ejca.2014.12.013>.
- Coles, C.E., Griffin, C.L., Kirby, A.M., Tittley, J., Agrawal, R.K., Alhasso, A., et al., 2017. IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet* 390, 1048–1060. [https://doi.org/10.1016/S0140-6736\(17\)31145-5](https://doi.org/10.1016/S0140-6736(17)31145-5).
- Kaidar-Person, O., Meattini, I., Zippel, D., Poortmans, P., 2020. Apples and oranges: comparing partial breast irradiation techniques. *Rep. Pract. Oncol. Radio.* 25, 780–782.
- Recht, A., Comen, E.A., Fine, R.E., Fleming, G.F., Hardenbergh, P.H., Ho, A.Y., et al., 2016. Postmastectomy radiotherapy: an American society of clinical oncology, american society for radiation oncology, and society of surgical oncology focused guideline update. *J. Clin. Oncol.* 34, 4431–4442. <https://doi.org/10.1200/JCO.2016.69.1188>.
- EBCTCG, 2014. (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet* 383, 2127–2135.
- Smith, B.D., Haffty, B.G., Hurria, A., Galusha, D.H., Gross, C.P., 2006. Postmastectomy radiation and survival in older women with breast cancer. *J. Clin. Oncol.* 24, 4901–4907.
- Tseng, M., Vellayappan, B., Choong, R., Appalanaido, G.K., Soon, Y.Y., 2020. Post mastectomy radiotherapy for elderly patients with intermediate risk (T1–2N1 or T3N0) breast cancer: a systematic review and meta-analysis. *Transl. Cancer Res* 9 (Suppl 1), S23–S28. DOI: [tcr.amegroups.com/article/view/30485](https://doi.org/10.2196/30485).
- Shirvani, S.M., Pan, I.W., Buchholz, T.A., Shih, Y.C., Hoffman, K.E., Giordano, S.H., et al., 2011. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. *Cancer* 117, 4595–4605. <https://doi.org/10.1002/ncr.26081>.
- Smith, B.D., Haffty, B.G., Smith, G.L., Hurria, A., Buchholz, T.A., Gross, C.P., 2008. Use of postmastectomy radiotherapy in older women. *Int. J. Radiat. Oncol. Biol. Phys.* 71, 98–106. <https://doi.org/10.1016/j.ijrobp.2007.09.006>.
- Harbeck, N., Rastogi, P., Martin, M., Tolane, S.M., Shao, Z.M., Fasching, P.A., et al., 2021. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann. Oncol.* 32, 1571–1581. <https://doi.org/10.1016/j.annonc.2021.09.015>.
- Rugo, H.S., O'Shaughnessy, J., Boyle, F., Toi, M., Broom, Blancas, R.I., et al., 2022. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. *Ann. Oncol.* 33, 616–627. <https://doi.org/10.1016/j.annonc.2022.03.006>.
- Johnston, S.R.D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z.M., et al., 2020. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *J. Clin. Oncol.* 38, 3987–3998. <https://doi.org/10.1200/JCO.20.02514>.
- Wang, S.-L., Fang, H., Song, Y.-W., Wang, W.-H., Hu, C., Liu, Y.-P., et al., 2019. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. *Lancet Oncol.* 20, 352–360. [https://doi.org/10.1016/S1470-2045\(18\)30813-1](https://doi.org/10.1016/S1470-2045(18)30813-1).
- Liu, L., Yang, Y., Guo, Q., Ren, B., Peng, Q., Zou, L., et al., 2020. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. *Radiat. Oncol.* 15, 17.
- Yarnold, J., 2019. Changes in radiotherapy fractionation-breast cancer. *Br. J. Radiol.* 92, 20170849. <https://doi.org/10.1259/bjr.20170849>.
- Haviland, J.S., Mannino, M., Griffin, C., Porta, N., Sydenham, M., Bliss, J.M., et al., 2018. Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. *Radiother. Oncol.* 126, 155–162.
- Milo, M.L., Lorincz, T., Nielsen, M.H., Kamy, C., Bechmann, T., Al-Rawi, S., et al., 2022. Acute toxicity after locoregional breast radiation therapy in the randomized DBCG SKAGEN trial 1. *Radiother. Oncol.* 170 (Suppl 1), OC-0829.
- Offersen, B., Alsner, J., Nielsen, H.M., Bechmann, T., Nielsen, M.H., Mjaaland, I., et al., 2022. DBCG phase III randomized trial of hypo- vs standard fractionated RT in 2879 pN+ breast cancer pts. *Radiother. Oncol.* 170 (Suppl 1), OC-0102.
- Wheatley, D., Haviland, J., Patel, J., Sydenham, M., Alhasso, A., Chan, C., et al., 2022. First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. *Radiother. Oncol.* 170 (Suppl 1), OC-0101.
- Hamaker, M.E., Bastiaannet, E., Evers, D., Water, W., Smorenburg, C.H., Maartense, E., et al., 2013. Omission of surgery in elderly patients with early stage breast cancer. *Eur. J. Cancer* 49, 545–552.
- Ojala, K., Meretoja, T.J., Mattson, J., Leidenius, M.H.K., 2019. Surgical treatment and prognosis of breast cancer in elderly - A population-based study. *Eur. J. Surg. Oncol.* 45, 956–962.
- Ward, S.E., Richards, P.D., Morgan, J.L., Holmes, G.R., Broggio, J.W., Collins, K., et al., 2018. Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survival. *Br. J. Surg.* 105, 1454–1463.
- Chargari, C., Kirova, Y.M., Laki, F., Savignoni, A., Dorval, T., Dendale, R., et al., 2010. The impact of the loco-regional treatment in elderly breast cancer patients: hypofractionated exclusive radiotherapy, single institution long-term results. *Breast* 19, 413–416.
- Courdi, A., Ortholan, C., Hannoun-Levi, J.M., Ferrero, J.M., Largillier, R., Balu-Maestro, C., et al., 2006. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. *Radiother. Oncol.* 79, 156–161.
- Hellman, S., Weichselbaum, R.R., 1995. Oligometastases. *J. Clin. Oncol.* 13, 8–10. doi: 10.1200/JCO.1995.13.1.8. PMID: 7799047.
- Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., et al., 2020. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann. Oncol.* 31, 1623–1649. <https://doi.org/10.1016/j.annonc.2020.09.010>.
- Guckenberger, M., Lievens, Y., Bouma, A.B., Collette, L., Dekker, A., deSouza, N.M., et al., 2020. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. *Lancet Oncol.* 21, e18–e28. [https://doi.org/10.1016/S1470-2045\(19\)30718-1](https://doi.org/10.1016/S1470-2045(19)30718-1).
- Corbin, K.S., Hellman, S., Weichselbaum, R.R., 2013. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. *J. Clin. Oncol.* 31, 1384–1390. <https://doi.org/10.1200/JCO.2012.45.9651>.
- Milano, M.T., Katz, A.W., Schell, M.C., Philip, A., Okunieff, P., 2008. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 72, 1516–1522. <https://doi.org/10.1016/j.ijrobp.2008.03.044>.
- Norihisa, Y., Nagata, Y., Takayama, K., Matsuo, Y., Sakamoto, T., Sakamoto, M., et al., 2008. Stereotactic body radiotherapy for oligometastatic lung tumors. *Int. J. Radiat. Oncol. Biol. Phys.* 72, 398–403. <https://doi.org/10.1016/j.ijrobp.2008.01.002>.
- Marazzi, F., Orlandi, A., Manfrida, S., Masiello, V., Di Leone, A., Massaccesi, M., et al., 2020. Diagnosis and treatment of bone metastases in breast cancer: radiotherapy, local approach and systemic therapy in a guide for clinicians. *Cancers (Basel)* 12, 2390. <https://doi.org/10.3390/cancers12092390>.
- Sharma, R.A., Plummer, R., Stock, J.K., Greenhalgh, T.A., Ataman, O., Kelly, S., et al., 2016. Clinical development of new drug-radiotherapy combinations. *Nat. Rev. Clin. Oncol.* 13, 627–642. <https://doi.org/10.1038/nrclinonc.2016.79>.
- Gomez, D.R., Tang, C., Zhang, J., Blumenschein Jr., G.R., Hernandez, M., Lee, J.J., et al., 2019. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. *J. Clin. Oncol.* 37, 1558–1565. <https://doi.org/10.1200/JCO.19.00201>.
- Iyengar, P., Wardak, Z., Gerber, D.E., Tumati, V., Ahn, C., Hughes, R.S., et al., 2018. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase

- 2 randomized clinical trial. *JAMA Oncol.* 4, e173501 <https://doi.org/10.1001/jamaoncol.2017.3501>.
- Ost, P., Reynnders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., et al., 2018. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. *J. Clin. Oncol.* 36, 446–453. <https://doi.org/10.1200/JCO.2017.75.4853>.
- Milano, M.T., Katz, A.W., Zhang, H., Huggins, C.F., Aujla, K.S., Okunieff, P., 2019. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. *Radiother. Oncol.* 131, 45–51. <https://doi.org/10.1016/j.radonc.2018.11.022>.
- Palma, D.A., Olson, R., Harrow, S., Gaede, S., Louie, A.V., Haasbeek, C., et al., 2019. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *Lancet* 393, 2051–2058. [https://doi.org/10.1016/S0140-6736\(18\)32487-5](https://doi.org/10.1016/S0140-6736(18)32487-5).
- Lievens, Y., Guckenberger, M., Gomez, D., Hoyer, M., Iyengar, P., Kindts, I., et al., 2020. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. *Radiother. Oncol.* 148, 157–166. <https://doi.org/10.1016/j.radonc.2020.04.003>.
- Correa, R.J., Salama, J.K., Milano, M.T., Palma, D.A., 2016. Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management. *Cancer J.* 22, 247–256. <https://doi.org/10.1097/PPO.0000000000000202>.
- Dagan, R., Lo, S.S., Redmond, K.J., Poon, I., Foote, M.C., Lohr, F., et al., 2016. A multinational report on stereotactic body radiotherapy for oligometastases: patient selection and follow-up. *Acta Oncol.* 55, 633–637. <https://doi.org/10.3109/0284186X.2015.1118659>.
- Donovan, E., Dhesy-Thind, S., Mukherjee, S., Kucharczyk, M., Swaminath, A., 2019. Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: a commentary on a survey of Canadian medical oncologists. *Breast J.* 25, 1222–1224. <https://doi.org/10.1111/tbj.13435>.
- Kwapisz, D., 2019. Oligometastatic breast cancer. *Breast Cancer* 26, 138–146. <https://doi.org/10.1007/s12282-018-0921-1>.
- Hong, J.C., Ayala-Peacock, D.N., Lee, J., Blackstock, A.W., Okunieff, P., Sung, M.W., et al., 2018. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. *PLoS One* 13, e0195149. <https://doi.org/10.1371/journal.pone.0195149>.
- Wong, A.C., Watson, S.P., Pitroda, S.P., Son, C.H., Das, L.C., Stack, M.E., et al., 2016. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). *Cancer* 122, 2242–2250. <https://doi.org/10.1002/ncr.30058>.
- Redmond, K.J., Lo, S.S., Dagan, R., Poon, I., Foote, M.C., Erler, D., et al., 2017. A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. *Future Oncol.* 13, 1081–1089. <https://doi.org/10.2217/fon-2016-0479>.
- deSouza, N.M., Liu, Y., Chiti, A., Oprea-Lager, D., Gebhart, G., Van Beers, B.E., et al., 2018. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer Imaging Group. *Eur. J. Cancer* 91, 153–163. <https://doi.org/10.1016/j.ejca.2017.12.012>.
- van de Vijver, M.J., He, Y.D., van't Veer, L.J., Dai, H., Hart, A.A.M., Voskuil, D.W., Schreiber, G.J., et al., 2002. A gene-expression signature as a predictor of survival in breast cancer. *N. Engl. J. Med.* 347, 1999–2009. <https://doi.org/10.1056/NEJMoa021967>.
- Patel, P.H., Palma, D., McDonald, F., Tree, A.C., 2019. The dandelion dilemma revisited for oligoprogession: treat the whole lawn or weed selectively? *Clin. Oncol. (R. Coll. Radio.)* 31, 824–833. <https://doi.org/10.1016/j.clon.2019.05.015>.
- Van den Begin, R., Engels, B., Collen, C., de Vin, T., Defauw, A., Dubaere, E., et al., 2019. The METABANK score: a clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. *Radiother. Oncol.* 133, 113–119. <https://doi.org/10.1016/j.radonc.2019.01.001>.
- Piroth, M.D., Krug, D., Feyer, P., Baumann, R., Combs, S., Duma, M.-N., et al., 2022. Oligometastasis in breast cancer - Current status and treatment options from a radiation oncology perspective. *Strahlenther. Onkol.* 198, 601–611. <https://doi.org/10.1007/s00066-022-01938-x>.
- Possanzini, M., Greco, C., 2018. Stereotactic radiotherapy in metastatic breast cancer. *Breast* 41, 57–66. <https://doi.org/10.1016/j.breast.2018.06.011>.
- Cortinovis, D., Malapelle, U., Pagni, F., Russo, A., Banna, G.L., Sala, E., Rolfo, C., 2021. Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. *Transl. Lung Cancer Res.* 10, 3385–3400. <https://doi.org/10.21037/tlcr-20-1067>.
- Lussier, Y.A., Xing, H.R., Salama, J.K., Khodarev, N.N., Huang, Y., Zhang, Q., et al., 2011. MicroRNA expression characterizes oligometastasis(es). *PLoS One* 6, e28650. <https://doi.org/10.1371/journal.pone.0028650>.
- Winnard, P.T., Farhad Vesuna, F., Muthukumar, S., Raman, V., 2020. Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity. *PLoS One* 15, e0242384. <https://doi.org/10.1371/journal.pone.0242384>.
- Rubino, S., Oliver, D.E., Tran, N.D., Vogelbaum, M.A., Forsyth, P.A., Yu, H.-H.M., et al., 2022. Improving brain metastases outcomes through therapeutic synergy between stereotactic radiosurgery and targeted therapies. *Front Oncol.* 12, 854402.
- Ingrosso, G., Becherini, C., Francolini, G., Lancia, A., Ali, E., Caini, S., et al., 2021. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. *Crit. Rev. Oncol. Hematol.* 159, 103242 <https://doi.org/10.1016/j.critrevonc.2021.103242>.
- Palumbo, I., Borghesi, S., Gregucci, F., Falivene, S., Fontana, A., Aristei, C., et al., 2021b. Omission of adjuvant radiotherapy for older adults with early-stage breast cancer particularly in the COVID era: A literature review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology). *J. Geriatr. Oncol.* 12, 1130–1135. <https://doi.org/10.1016/j.jgo.2021.05.008>.
- Cushman, T.R., Caetano, M.S., Welsh, J.W., Verma, V., 2018. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. *Immunotherapy* 10, 851–860. <https://doi.org/10.2217/imt-2018-0019>.
- Guénolé, M., Lucia, F., Bourbonne, V., Dissaux, G., Reygagne, E., Goasduff, G., et al., 2020. Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases. *BMC Cancer* 20, 991. <https://doi.org/10.1186/s12885-020-07491-z>.
- Meattini, I., Andrascchke, N., Kirby, A.M., Sviri, G., Offersen, B.V., Poortmans, P., et al., 2020. Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. *Clin. Transl. Oncol.* 22, 1698–1709. <https://doi.org/10.1007/s12094-020-02333-7>.
- Kim, J.M., Miller, J.A., Kotecha, R., Chao, S.T., Ahluwalia, M.S., Peereboom, D.M., et al., 2019b. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. *Neuro Oncol.* 21, 659–668. <https://doi.org/10.1093/neuonc/noz006>.
- Mills, M.N., Walker, C., Thawani, C., Naz, A., Figura, N.B., Kushchayev, S., et al., 2021. Trastuzumab emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. *BMC Cancer* 21, 223. <https://doi.org/10.1186/s12885-021-07971-w>.
- Parsai, S., Miller, J.A., Juloori, A., Chao, S.T., Kotecha, R., Mohammadi, A.M., et al., 2020. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. *J. Neurosurg.* 132, 503–511. <https://doi.org/10.3171/2018.10.JNS182340>.
- Yang, Y., Luo, J., Chen, X., Yang, Z., Mei, X., Ma, J., et al., 2020. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. *J. Exp. Clin. Oncol.* 39, 188. <https://doi.org/10.1186/s13046-020-01693-w>.
- Figura, N.B., Potluri, T.K., Mohammadi, H., Oliver, D.E., Arrington, J.A., Robinson, T.J., et al., 2019. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. *J. Neurooncol.* 144, 583–589. <https://doi.org/10.1007/s11060-019-03260-6>.
- Kim, K.N., Shah, P., Clark, A., Freedman, G.M., Dastgheyb, S., Barskyet, A.R., et al., 2021. Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer. *Breast* 60, 163–167. <https://doi.org/10.1016/j.breast.2021.10.001>.
- Ratosa, I., Orazem, M., Scoccimarro, E., Steinacher, M., Dominici, L., Aquilano, M., et al., 2020. Cyclin-dependent kinase 4/6 inhibitors combined with radiotherapy for patients with metastatic breast cancer. *Clin. Breast Cancer* 20, 495–502.
- Petroni, G., Buque, A., Yamazaki, T., Bloy, N., Di Liberto, M., Chen-Kiang, S., et al., 2021. Radiotherapy delivered before CDK4/6 inhibitors mediates superior therapeutic effects in ER+ breast cancer. *Clin. Cancer Res.* 27, 1855–1863. <https://doi.org/10.1158/1078-0432.CCR-20-3871>.
- Demaria, S., Ng, B., Devitt, M.L., Babb, J.S., Kawashima, N., Liebes, L., et al., 2004. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. *Int. J. Radiat. Oncol. Biol. Phys.* 58, 862–870. <https://doi.org/10.1016/j.ijrobp.2003.09.012>.
- Formenti, S.C., Demaria, S., 2009. Systemic effects of local radiotherapy. *Lancet Oncol.* 10, 718–726 [https://doi.org/10.1016/S1470-2045\(09\)70082-8](https://doi.org/10.1016/S1470-2045(09)70082-8).
- Theelen, W.S.M.E., Chen, D., Verma, V., Hobbs, B.P., Peulen, H.M.U., Aerts JgVj., et al., 2020. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomized trials. *Lancet. Respir. Med.* 9, 467–475.
- Ho, A.Y., Barker, C.A., Arnold, B.B., Powell, S.N., Hu, Z.I., Guicalp, A., et al., 2020. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. *Cancer* 126, 850–860. <https://doi.org/10.1002/ncr.32599>.
- Muraro, E., Furlan, C., Avanzo, M., Martorelli, D., Comaro, E., Rizzo, A., et al., 2017. Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer. *Front Immunol.* 8, 1476. <https://doi.org/10.3389/fimmu.2017.01476>.
- Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., et al., 2021. Bone health in cancer: ESMO clinical practice guidelines. *Ann. Oncol.* 31, 1650–1663. <https://doi.org/10.1016/j.annonc.2020.07.019>.
- Pichon, B., Campion, L., Delpont, G., Thillays, F., Carrie, C., Cellier, P., et al., 2016. High-dose hypofractionated radiation therapy for noncompressive vertebral metastases in combination with zoledronate: a phase 1 study. *Int. J. Radiat. Oncol. Biol. Phys.* 96, 840–847. <https://doi.org/10.1016/j.ijrobp.2016.07.027>.
- Makhlin, I., Fox, K., 2020. Oligometastatic breast cancer: is this a curable entity? A contemporary review of the literature. *Curr. Oncol. Rep.* 22, 15. <https://doi.org/10.1007/s11912-020-0867-2>.
- 2021 Breast Cancer Association Consortium. Breast cancer risk genes - Association analysis in more than 113,000 women. *N Engl J Med.* 2021; 384:428–39. DOI: 10.1056/NEJMoa1913948.
- Hu, C., Hart, S.N., Gnanaolivu, R., Huang, H., Lee, K.Y., Na, J., et al., 2021. A population-based study of genes previously implicated in breast cancer. *N. Engl. J. Med.* 384, 440–441. <https://doi.org/10.1056/NEJMoa2005936>.
- Brose, M.S., Rebbeck, T.R., Calzone, K.A., Stopfer, J.E., Nathanson, K.L., Weber, B.L., 2002. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. *J. Natl. Cancer Inst.* 94, 1365–1372. <https://doi.org/10.1093/jnci/94.18.1365>.
- Lakhani, S.R., Jacquemier, J., Sloane, J.P., Gusterson, B.A., Anderson, T.J., van de Vijver, M.J., et al., 1998. Multifactorial analysis of differences between sporadic

- breast cancers and cancers involving BRCA1 and BRCA2 mutations. *J. Natl. Cancer Inst.* 90, 1138–1145. <https://doi.org/10.1093/jnci/90.15.1138>.
- Paluch-Shimon, S., Evron, E., 2019. Targeting DNA repair in breast cancer. *Breast* 47, 33–42. <https://doi.org/10.1016/j.breast.2019.06.007>.
- Pierce, L.J., Haffty, B.G., 2011. Radiotherapy in the treatment of hereditary breast cancer. *Semin Radiat. Oncol.* 21, 43–50. <https://doi.org/10.1016/j.semradonc.2010.08.008>.
- Venkitaraman, A.R., 2002. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 108, 171–182. [https://doi.org/10.1016/s0092-8674\(02\)00615-3](https://doi.org/10.1016/s0092-8674(02)00615-3).
- Copson, E.R., Maishman, T.C., Tapper, W.J., Cutress, R.I., Greville-Heygate, S., Altman, D.G., et al., 2018. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. *Lancet Oncol.* 19, 169–180. [https://doi.org/10.1016/S1470-2045\(17\)30891-4](https://doi.org/10.1016/S1470-2045(17)30891-4).
- Stjepanovic, N., Villacampa, G., Nead, K.T., Torres-Esquius, S., Melis, G.G., Nathanson, K.L., et al., 2020. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: maximising bias-reduction. *Eur. J. Cancer* 132, 53–60. <https://doi.org/10.1016/j.ejca.2020.03.009>.
- Carbine, N.E., Lostumbo, L., Wallace, J., Ko, H., 2018. Risk-reducing mastectomy for the prevention of primary breast cancer. *Cochrane Database Syst. Rev.* 4, Cd002748. <https://doi.org/10.1002/14651858.CD002748.pub4>.
- Heemskerk-Gerritsen, B.A.M., Jager, A., Koppert, L.B., Obdeijn, A.I.-M., Collée, M., Meijers-Heijboer, H.E.J., et al., 2019. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 177, 723–733. <https://doi.org/10.1007/s10549-019-05345-2>.
- Hartmann, L.C., Sellers, T.A., Schaid, D.J., Frank, T.S., Soderberg, C.L., Sitta, D.L., et al., 2001. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J. Natl. Cancer Inst.* 93, 1633–1637. <https://doi.org/10.1093/jnci/93.21.1633>.
- Meijers-Heijboer, H., van Geel, B., van Putten, W.L., Henzen-Logmans, S.C., Seynaeve, C., Menke-Pluymers, M.B., et al., 2001. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N. Engl. J. Med.* 345, 159–164. <https://doi.org/10.1056/NEJM200107193450301>.
- Evron, E., Avraham, A., Paluch-Shimon, S., 2014. Systemic treatment considerations for women with BRCA1/2-associated breast cancer. *Curr. Breast Cancer Rep.* 6, 139–145. <https://doi.org/10.1007/s12609-014-0156-x>.
- Goodwin, P.J., Phillips, K.A., West, D.W., Ennis, M., Hopper, J.L., John, E.M., et al., 2012. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. *J. Clin. Oncol.* 30, 19–26. <https://doi.org/10.1200/JCO.2010.33.0068>.
- Huzarski, T., Byrski, T., Gronwald, J., Gorski, B., Domagala, P., Cybulski, C., et al., 2013. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. *J. Clin. Oncol.* 31, 3191–3196. <https://doi.org/10.1200/JCO.2012.45.3571>.
- Maishman, T., Cutress, R.I., Hernandez, A., Gerti, S., Copson, E.R., Durcan, L., et al., 2017. Local recurrence and breast oncological surgery in young women with breast cancer: the POSH observational Cohort study. *Ann. Surg.* 266, 165–172. <https://doi.org/10.1097/SLA.0000000000001930>.
- Vallard, A., Magné, N., Guy, J.B., Espenel, S., Rancoule, C., Diao, P., et al., 2019. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view. *Br. J. Radiol.* 92, 20170657. <https://doi.org/10.1259/bjr.20170657>.
- Davey, M.G., Davey, C.M., Ryan, E.J., Lowery, A.J., Kerin, M.J., 2021. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis. *Breast* 56, 26–34. <https://doi.org/10.1016/j.breast.2021.02.001>.
- Tung, N.M., Boughey, J.C., Pierce, L.J., Robson, R.E., Bedrosian, I., Dietz, J.R., et al., 2020. Management of hereditary breast cancer: american society of clinical oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. *J. Clin. Oncol.* 38, 2080–2106. <https://doi.org/10.1200/JCO.20.00299>.
- Morrow, M., 2022. Surgery and prophylactic surgery in hereditary breast cancer. *Breast* 62, S63–S66. <https://doi.org/10.1016/j.breast.2021.12.010>.
- van den Broek, A.J., Schmidt, M.K., van 't Veer, L.J., Oldenburg, H.S.A., Rutgers, E.J., Russel, N.S., et al., 2019. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. *Ann. Surg.* 270, 364–372. <https://doi.org/10.1097/SLA.0000000000002804>.
- Bernier, J., Poortmans, P., 2015. Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review. *Breast* 24, 100–106. <https://doi.org/10.1016/j.breast.2014.12.003>.
- Kirova, Y.M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R.J., This, P., et al., 2010. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. *Breast Cancer Res Treat.* 120, 119–126. <https://doi.org/10.1007/s10549-009-0685-6>.
- Kirova, Y.M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., Fourquet, A., 2005. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. *Eur. J. Cancer* 41, 2304–2311. <https://doi.org/10.1016/j.ejca.2005.02.037>.
- Pierce, L.J., Levin, A.M., Rebbeck, T.R., Ben-David, M.A., Friedman, E., Solin, L.J., et al., 2006. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. *J. Clin. Oncol.* 24, 2437–2443. <https://doi.org/10.1200/JCO.2005.02.7888>.
- Pierce, L.J., Phillips, K.A., Griffith, K.A., Buys, S., Gaffney, D.K., Moran, M.S., et al., 2010. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. *Breast Cancer Res Treat.* 121, 389–398. <https://doi.org/10.1007/s10549-010-0894-z>.
- Valachis, A., Nearchou, A.D., Lind, P., 2014. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. *Breast Cancer Res Treat.* 144, 443–455. <https://doi.org/10.1007/s10549-014-2890-1>.
- Shanley, S., McReynolds, K., Ardern-Jones, A., Ahern, R., Fernando, I., Yarnold, J., et al., 2006. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. *Clin. Cancer Res* 12, 7025–7032. <https://doi.org/10.1158/1078-0432.CCR-06-1244>.
- Pierce, L.J., Strawderman, M., Narod, S.A., Olivetto, I., Eisen, A., Dawson, L., et al., 2000. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. *J. Clin. Oncol.* 18, 3360–3369. <https://doi.org/10.1200/JCO.2000.18.19.3360>.
- van den Broek, A.J., van 't Veer, L.J., Hoening, M.J., Cornelissen, S., Broeks, A., Rutgers, E.J., et al., 2016. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. *J. Clin. Oncol.* 34, 409–418. <https://doi.org/10.1200/JCO.2015.62.3942>.
- Metcalfe, K., Lynch, H.T., Ghadirian, P., Tung, N., Olivetto, I., Warner, E., et al., 2004. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *J. Clin. Oncol.* 22, 2328–2335. <https://doi.org/10.1200/JCO.2004.04.033>.
- Kuchenbaecker, K.B., Hopper, J.L., Barnes, D.R., Phillip, K.-A., Mooij, T.M., Ruos-Bloom, M.-J., et al., 2017. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *Jama* 317, 2402–2416. <https://doi.org/10.1001/jama.2017.7112>.
- Schlosser, S., Rabinovitch, R., Shatz, Z., Galper, S., Shahadi-Dromi, I., Finkel, S., et al., 2020. Radiation-associated secondary malignancies in BRCA mutation carriers treated for breast cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 107, 353–359. <https://doi.org/10.1016/j.ijrobp.2020.02.020>.
- Stovall, M., Smith, S.A., Langholz, B.M., Boice Jr., J.D., Shore, R.E., Andersson, M., et al., 2008. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. *Int. J. Radiat. Oncol. Biol. Phys.* 72, 1021–1030. <https://doi.org/10.1016/j.ijrobp.2008.02.040>.
- Hoening, M.J., Aleman, B.M., Hauptmann, M., Baaijens, M.H.A., Klijn, J.G.M., Noyon, R., et al., 2008. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. *J. Clin. Oncol.* 26, 5561–5568. <https://doi.org/10.1200/JCO.2007.16.0192>.
- Bernstein, J.L., Thomas, D.C., Shore, R.E., Robson, M., Boice Jr., J.D., Stovall, M., et al., 2013. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. *Eur. J. Cancer* 49, 2979–2985. <https://doi.org/10.1016/j.ejca.2013.04.028>.
- Elzaby, M., Lees, B., Maturen, K.E., Barroillet, L., Wisinski, K.B., Schrag, S., et al., 2019. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. *Radiology* 291, 554–569. <https://doi.org/10.1148/radiol.2019181814>.
- Rebbeck, T.R., Friebe, T., Lynch, H.T., Neuhausen, S.L., 2004. van't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J. Clin. Oncol.* 22, 1055–1062. <https://doi.org/10.1200/JCO.2004.04.188>.
- Robson, M., Gilewski, T., Haas, B., Levin, D., Borgen, P., Rajan, P., et al., 1998. BRCA-associated breast cancer in young women. *J. Clin. Oncol.* 16, 1642–1649. <https://doi.org/10.1200/JCO.1998.16.5.1642>.
- Metcalfe, K., Eisen, A., Senter, L., Armel, S., Bordeleau, L., Meschino, W.S., et al., 2019. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. *Br. J. Cancer* 121, 15–21. <https://doi.org/10.1038/s41416-019-0446-1>.
- Sacks, G.D., Morrow, M., 2020. Addressing the dilemma of contralateral prophylactic mastectomy with behavioral science. *J. Clin. Oncol.* 38, 269–272. <https://doi.org/10.1200/JCO.20.02239>.
- Manchanda, R., Burnell, M., Gaba, F., et al., 2019. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study. *BJOG* 126, 784–794. <https://doi.org/10.1111/1471-0528.15654>.
- Evron, E., Ben-David, A.M., Goldberg, H., Fried, G., Kaufman, B., Catane, R., et al., 2019. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. *Ann. Oncol.* 30, 412–417. <https://doi.org/10.1093/annonc/mdy515>.
- Poortmans, P.M.P., Kaidar-Person, O., 2019. Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment. *Ann. Oncol.* 30, 348–350. <https://doi.org/10.1093/annonc/mdz014>.
- Narod, S.A., 2019. Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer. *Ann. Transl. Med.* 7, 165. <https://doi.org/10.21037/atm.2019.03.27>.

Cynthia Aristei, MD is Full Professor of Radiation Oncology in the Department of Medicine and Surgery at the University of Perugia, Italy and Head of the Radiation Oncology Unit at Perugia General Hospital. Breast and gynecological cancer, such as hematological malignancies, are her main field of interest in radiation oncology. She is involved in clinical and translational research project and has been presenting her research findings at Italian and International Conferences for almost 30 years. Furthermore, she has engaged in organizing national and international meetings. She is an ASTRO, ESTRO and ASCO member.

Yasemin Bolukbasi, MD is Chair & Professor of Department of Radiation Oncology at Koc University School of Medicine since 2020, as well as being an adjunct Professor of U.T. M. D. Anderson Cancer Center, Department of Radiation Oncology, and Professor of American Hospital-MD Anderson Radiation Treatment Center in Istanbul. Dr. Bolukbasi is a reviewer

for a number of international journals and has authored numerous articles in peer-reviewed journals and book chapters. She is a member of ESTRO, ASTRO and “Turkish Society for Radiation Oncology”.

Orit Kaidar-Person, MD is radiation oncologist & the Head of Breast Cancer Radiotherapy Unit at Sheba Medical Center, Ramat Gan, and senior lecturer at Tel Aviv University, Israel. She is member of the European Society for Radiotherapy and Oncology (ESTRO) breast cancer faculty, of the educational faculty of FALCON-ESTRO (Fellowship in Anatomic delineation and CONtouring) and of the ESTRO-ACROP breast cancer focus group. She also is currently a foreign PhD student at GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands, focusing on improving radiation therapy outcomes of breast cancer patients after mastectomy, especially related to breast reconstruction.

Raphael Pfeffer, MD is Head of Oncology Institute, Assuta Medical Center, Tel Aviv. Research projects included the effects of combined modality therapy of radiation with chemotherapy and hyperthermia and the combination of novel biological agents with radiotherapy. Clinical projects included stereotactic irradiation for both CNS and non-CNS tumors and MR guided focused ultrasound in cancer treatment. Participated in EORTC Radiotherapy Group clinical studies and other locally initiated and international clinical studies. Member of the following scientific organizations: ASTRO, ESTRO, ASCO. Organizing committee, 3rd biennial meeting of ISRS (International Society for RadioSurgery), 2001 and member of the scientific committee of ISRS in 2003, 2005 and 2009. Chairman of the 2010 annual meeting of the Israel Society for Clinical Oncology and Radiation Therapy. Professional positions: 2014–2021, board member & treasurer ISCOR (Israel Society for Clinical Oncology and Radiation Therapy). Chairman of the Israel Radiotherapy Group 2001–2006, 2004–2014 Chairman of the Radiotherapy Examination Committee of the Israel Board of Clinical Oncology and Radiotherapy. 1998–2012 Member of the Helsinki Ethics Committee at the Chaim Sheba Medical Center. 2017- Member of committee for revision of European Syllabus in Radiotherapy & Oncology.

Meritxell Arenas Prat, MD, PhD (ORCID number: 0000-0003-0815-2570) is specialist in Radiation Oncology. In 2000 she started working at the Hospital Universitari Sant Joan de Reus (HUSJR) (Tarragona, Catalonia, Spain) as first specialist responsible of Breast Cancer Radiotherapy. In 2008 she realized the doctoral thesis in basic research (Radiobiology) in *University of Barcelona* (“Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice”). In 2010 was selected as Head of Radiation Oncology Department at the HUSJR, where she is still serving. She is Coordinator of Radiation Oncology Research Group at Institut d'Investigacions Sanitàries Pere Virgili (IISPV), Associate Professor at Universitat Rovira i Virgili (URV) and President of Catalan Oncology Society. The main research line of Dra. Arenas is the identification of molecular biomarkers based on energy metabolism, oxidative stress and immune system in patients with breast cancer.

Liesbeth Boersma, MD is radiation oncologist at Dept. Radiation Oncology (Maastro), GROW-School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands, and professor at the University of Maastricht, The Netherlands. Her fields of interest include radiotherapy for breast cancer, shared decision making and innovation implementation. She is member of the Dutch Committee for Breast Cancer Guidelines, (co-) PI of several studies, and member of the Dutch Breast Cancer Research Group (BOOG) Locoregional Treatment. She is chair of the Dutch Platform for Proton Therapy. In addition, she is faculty member of the ESTRO course multidisciplinary treatment of breast cancer, and of the ESTRO-ACROP guideline committee, breast cancer subgroup.

Antonella Ciabattini MD is radiation oncologist at the Radiotherapy Unit in San Filippo Neri Hospital, ASL Roma 1, Rome, Italy. She graduated at the Catholic University of Rome in 1989 and specialized in Radiation Oncology in 1993 in the same University and in Diagnostic Radiology in 2007 in Campus Biomedico University of Rome. Since 1999 she has been working at San Filippo Neri Hospital with many interests, acquiring a high degree of specialization for breast, gastrointestinal and head and neck cancers. She is referent for Quality, Training and Research in her institution. In the last 20 years she has been actively working in the field of intraoperative radiotherapy, being member of the board of the International Intraoperative Radiotherapy Society (ISIORT). She is member of the AIRO and ESTRO societies and has been working in AIRO Breast Cancer Group, as coordinator in the years 2017–2019. She is adjunct professor in the degree courses for Physiotherapists and Technicians for Medical Radiology and Radiotherapy at Sapienza University of Rome.

Charlotte Coles is Professor of Breast Cancer Clinical Oncology and Deputy Head of Department of Oncology, University of Cambridge. Her research aims are to provide cancer patients with the best chance of cure with least side effects by personalising radiation techniques. She was awarded a National Institute of Health Research (NIHR) Research Professorship in 2019 for her risk-adapted breast RT research programme. Charlotte successfully led the Cancer Research UK (CRUK) Radiation Research Centre of Excellence award at Cambridge to develop a translational research pipeline from basic radiation research through to clinical trials, with a focus on DNA damage response and genetic approaches to define drug-RT combinations. She is Chief Investigator for 5 multicentre clinical trials: IMPORT LOW & HIGH, PRIMETIME, NEO-RT and PARABLE. Charlotte chaired the NCRI Early Disease Breast Cancer sub-group and is a member of the NIHR Health Technology Assessment Committee and the CRUK Clinical Research Committee. International roles include scientific tracks/faculty for SABCS, ESMO, EBCC and ESTRO. Charlotte was Editor-in-Chief of *Clinical Oncology* journal from 2015 to 21. She stepped down in 2021 to lead the Lancet Commission for Breast Cancer.

Pierfrancesco Franco, MD, PhD is a radiation and clinical oncologist. He is currently appointed as Associate Professor of Radiation Oncology, at the Department of Translational Medicine, University of Eastern Piedmont, in Novara, Italy. He is specifically working on breast and head and neck cancers and gastrointestinal malignancies. He is involved in clinical research and cancer education collaborating with the European Society of radiotherapy and Oncology (ESTRO), the European School of Oncology (ESO) and the European Organization for Cancer Research and Treatment (EORTC). He has a special interest in psycho oncology and professional well-being.

Marco Krengli is radiation oncologist at the Department of Oncology of the University Hospital “Maggiore della Carità” in Novara and full professor and dean of the School of Medicine at the University of “Piemonte Orientale”, Italy. The main research fields include head and neck and breast cancer, particle therapy and intraoperative radiotherapy. He is President-elect of the Italian Association for Radiotherapy and Clinical Oncology (AIRO).

Maria Cristina Leonardi is a Deputy Director of the Division of Radiation Therapy at the European Institute of Oncology, Milan, Italy, where she has worked since 1997. She is member of the Board of Specialization School in Radiotherapy at University of Milan and of ISORT Europe. She has experience in intraoperative radiotherapy and IMRT treatments. Pivotal publications focus on breast cancer. The main field of interest addresses partial breast irradiation and hypofractionation.

Fabio Marazzi is radiation oncologist and medical oncologist and the head of Radiochemotherapy Day Hospital Art4Art Unit at Fondazione Policlinico Agostino Gemelli IRCCS. He is member of European Society for Radiotherapy and Oncology (ESTRO) and European Society for Medical Oncology (ESMO). He is interested in all solid tumors field, in particular breast cancer, for which manage both systemic therapy and radiotherapy.

Valeria Masiello is radiation oncologist and she works at Radiochemotherapy Day Hospital Art4Art Unit at Fondazione Policlinico Agostino Gemelli IRCCS. She is member of Associazione Italiana Radioterapia Oncologica (AIRO), European Society for Radiotherapy and Oncology (ESTRO) and European Society for Medical Oncology (ESMO). Her fields of interest is in breast cancer and artificial intelligence for big data extraction.

Icro Meattini is radiation and clinical oncologist consultant at the Florence University Hospital, and associate professor at the Department of Clinical and Experimental Biomedical Sciences “M. Serio” of the University of Florence, Italy. He is actively involved in ESTRO, EORTC, ESMO, ESO, and ESSO networks. Currently he is member of the steering committee of the EORTC breast cancer group and of the EORTC radiation oncology scientific council and founder of the Clinical Oncology Breast Cancer Group (COBCG) cooperative network. He is member of the ESTRO-ACROP breast cancer focus group and of the ESTRO breast cancer faculty.

Ángel Montero Luis, MD, PhD, is Professor at the Radiation Oncology Department of the Clara Campal Integral Oncology Center (CIOCC), University Hospital HM Sanchinarro, Madrid, Spain. His educational activities include professor at the University of Francisco de Vitoria, University of Murcia, as well as in Center for Biosanitary Professions HM Hospitals. He is principal investigator and collaborating researcher in several national and international studies and (co-)author of more than 50 scientific publications and 40 chapters in (inter)national books. Finally, he is coordinator of the Spanish Group of Radiation Oncology in Breast Cancer (GEORM) co-inventor of the IRMAPRON® device, immobilizer for radiotherapy of the breast in the prone position, and co-director of the iOncoR mobile application.

Birgitte V. Offersen is a clinical oncologist, phd, at Department of Experimental Clinical Oncology & Dept Oncology & Danish Center for Particle Therapy at Aarhus University Hospital, Denmark. She is clinical professor at Aarhus University, chair of the Danish Breast Cancer Group (DBCg) Board and chair of the DBCg RT Committee. She is PI on 5 national and international clinically controlled randomised trials developing new radiation therapies for early breast cancer patients. In addition, she is faculty member of the ESTRO course on multidisciplinary treatment of breast cancer and of the ESTRO guideline committee breast cancer subgroup. Main interests are radiation therapy, breast cancer, tumour microenvironment, clinical trials, shared decision making and patient involvement.

Lurdes Trigo is a Senior Graduate Assistant in Radioncology and the head of Brachytherapy Service of the Dept. Sciences of Image and Radioncology at Instituto Português Oncologia Porto, Portugal and is the President of the Portuguese Society of Radiation Oncology, since 2009. She received her MD in Oporto University, 1982 and the title of Master in Oncology (MSc) also in Oporto University, 1997. As a brachytherapy expert her research work is about this field (breast and prostate cancer and head and neck focus) and is the PI of several clinical trials. She is Member of editorial board: “Reports of Practical Oncology and Radiotherapy” (RPOR), 2022; Co-editor & Revisor Reports of Practical Oncology and Radiotherapy” (RPOR), 2010 – 2021 and Revisor of Journals: “The Breast” and “Radiotherapy & Oncology” (Green Journal), 2021–2022. She has been UEMS Radiation Oncology and Radiotherapy and National Societies representative at ESTRO, while he is also the local organizer of many ESTRO courses held in Porto, Portugal, for years.

Celine Bourgier is radiation oncologist at the department of radiation oncology of the Institut du Cancer de Montpellier, France, and Professor at the University of Montpellier, France. She is strongly involved in breast cancer field as PI of several clinical trials. She is also actively involved in late radio-induced toxicities prevention and management as PI of

several clinical trials and as coordinator in Radiobiology & targeted radiotherapy team of radiobiology research, INSERM U1194, Montpellier, France.

Domenico Genovesi, MD, is the radiation oncologist leading the radiotherapy unit in Chieti Hospital, "G. d'Annunzio" Chieti-Pescara University, Italy. He received his MD in Chieti in 1994. He specialized in Radiation Oncology at the Catholic University of Rome in 1998. Since 1999 he has been working at the University Hospital of Chieti as a Radiation Oncologist. In 2011 he took up the position of Associate Professor of Radiation Oncology at the University of Chieti-Pescara. Since 2021 he has been full professor of Radiation Oncology at the University of Chieti-Pescara. His research has been transversal to all fields of Radiation Oncology mainly concerning gastrointestinal cancers, breast, urogenital and gynecological cancers. In addition, he is member of the AIRO and ESTRO societies.

Vassilis Kouloulis is radiation oncologist and the head of radiotherapy unit of the 2nd Dept. of Radiology at ATTIKON University Hospital, Athens, Greece. He is a Professor of Radiation Oncology in Medical School of the National and Kapodistrian University of Athens, Greece. He has also a degree of Physics along with a PhD in Biomedical Engineering. His field of interest are breast, prostate and head-neck cancer. He is PI of several studies in Greece. He is the President of the Greek Society of Radiation Oncology as well as the Greek Society of Hyperthermic Oncology. He is a member of SAG of ESTRO, while he is also the local organizer of many ESTRO courses held in Greece, for several years. He is also the president of the scientific committee of stereotactic radiotherapy of the Greek Ministry of Health.

Alessio G. Morganti is professor of radiotherapy and chair of the radiotherapy department of the Bologna university, chair of the postgraduate program in radiotherapy, professor in medical school, PhD program of oncology, and RTT school (Bologna University). He is also professor in the postgraduate program in radiotherapy, of the Catholic University (Rome), coordinator of 32 research projects, lecturer in international teaching courses (ESTRO, IAEA), member of the editorial board of several journals and reviewer of scientific projects for several international scientific societies and the Italian Ministry of University. He is involved in several successful European and institutional grants.

Bruno Meduri is radiation oncologist at the department of radiation oncology of the University Hospital of Modena, Italy. His special interests include breast cancer and gastrointestinal cancer. He is former council member of the Italian Association of Radiation Oncology (AIRO) Working Group on Breast cancer and founding member of the Clinical Oncology Breast Cancer Group (COBCG).

Nadia Pasinetti is head radiation and clinical oncologist and palliative care at the ASST Valcamonica Hospital, and Researcher at the Department of Department of Medical-Surgical Specialties, Radiology Sciences and Public Health of the University of Brescia, Italy. She has also a PhD in Radiobiology. Her field of interest are breast and head-neck cancer. She is active member of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) breast cancer study group and of the Clinical Oncology Breast Cancer Group (COBCG) cooperative network.

Sara Pedretti MD is a radiation oncologist in ASST Spedali Civili di Brescia, Italy. She had a master's degree in combination of new oncological drugs and radiotherapy. Her field of interest is breast and central nervous system cancer. She is PI of several studies in Italy. She is an active member of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) for breast cancer.

Elisabetta Perrucci MD, is a Radiation Oncologist, Gynaecological cancer and Brachytherapy expert, Deputy Director and Quality Manager at Radiation Oncology Section of Perugia General Hospital, Italy. Interests in breast cancer radiotherapy, gynecological cancer radiotherapy, brachytherapy, stereotactic radiotherapy research.

Sofia Rivera, MD, PhD, is the radiation oncologist leading the radiotherapy breast unit in Institute Gustave Roussy, Villejuif, France. She received her MD in Dijon in 2008, and a PhD in Radiobiology from Paris University in 2016. Her research work in the field of radiobiology and breast cancer focus on combination of new drugs with radiotherapy and hypofractionation. She is PI of several clinical trials in the field of breast cancer with a major impact on the health care system. Sofia Rivera is chair of the UNICANCER French national group of translational research and development in radiation oncology (UNI-TRAD). In addition, she is faculty member of the ESTRO course on advanced skills in modern radiotherapy.

Vincenzo Tombolini, MD is Full Professor of Radiation Oncology at University Sapienza of Rome - Department of Radiological, Oncological and Anatomic-Pathological Sciences. He is Head of Department of Radiotherapy at Policlinico Umberto I Rome and Head of Integrated Assistential Department of Hematology, Oncology and Dermatology at Policlinico Umberto I Rome. Areas of interest are Radiobiology, Prostate Cancer, Head and Neck Cancer and Flash-Therapy. AIRO Member AIRB Member

Cristiana Vidali is specialized in Radiation Oncology and was Senior Assistant in the Department of Radiotherapy at Trieste University Hospital, Italy, until the end of 2019. Her fields of interest include: breast cancer, gynaecological tumours and intraoperative radiation therapy (IORT). She was Adjunct Professor in the School of Specialization of Gynaecology and Obstetrics of the University of Trieste from 1996 to 2019 and taught in the International Master of Advanced Studies in Medical Physics at the International Center for Theoretical Physics (ICTP) from 2017 to 2020 and in the Master of Interventional Oncology of the Università Cattolica del Sacro Cuore in Rome from 2020 to 2022. She is a member of the AIRO, of the ESTRO and of the IORT. She was the Coordinator of the AIRO National Study Group for Breast Cancer (2013–2014) and Deputy Coordinator of the AIRO National Study Group for Interventional Radiotherapy – IORT (2018–2019).

Vincenzo Valentini is Full Professor of Radiation Oncology at the School of Medicine of the Università Cattolica S.Cuore of Rome and Director of Department of Radiology, Radiation Oncology and Hematology at Fondazione Policlinico Universitario A.Gemelli -IRCCS of Rome. He is author of publications in peer-reviewed journal as well as book chapters and international guidelines. He was President of ESTRO (European Society of Radiotherapy and Oncology) in 2011–2014.

Philip Poortmans is radiation oncologist at the department of radiation oncology of the Iridium Network, Wilrijk-Antwerp, and associate professor at the University of Antwerp, Belgium. His special interests include breast cancer and FLASH radiation therapy. He is former president of the European Society for Radiotherapy & Oncology (ESTRO) and of the European Cancer Organisation. He is actively involved in research activities of the EORTC and is faculty member for breast cancer-related educational activities of ESTRO, ESSO, ESMO and ESO, including as course director for ESTRO's breast cancer courses and chairperson of the ESTRO-ACROP breast cancer focus group.